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The three opioid receptor subtypes, mu (µ), delta (δ) and kappa (κ) have long been associated 
with analgesia. Traditional opioid analgesics exert their effects through µ receptors located in 
the CNS. Recent studies suggest that the development of opioid analgesics displaying dual 
properties of µ agonism and δ antagonism could be of benefit by retaining potent analgesic 
properties while reducing the development of tolerance with chronic administration. UMB 425 
displays high affinity at the µ receptor (Ki = 3.2 ± 0.14 nM), moderate affinity at the δ and κ 
receptor In vitro [35S]GTPγS functional assay results indicate that UMB 425 acts as partial 
agonist at the µ receptor,  whilst having competitive antagonistic properties at the δ receptor. 
UMB 425 displays potent acute analgesic activity in vivo for both the hot plate and tail-flick 
assays, comparable to morphine itself. To ensure proper opioid-induced mechanisms 
pretreatment studies were performed using naloxone, a non-selective opioid antagonist, and 
nor-BNI, a selective κ-antagonist. Naloxone attenuates the analgesic effects induced by an 
acute ED90 of UMB 425, while nor-BNI shows no significant reduction. A chronic dosing 
paradigm was designed to determine UMB 425 induced analgesic tolerance. UMB 425 
maintains significantly higher levels of analgesia compared to morphine on the fifth day of this 
chronic dosing paradigm. A dose-response challenge performed on the sixth day of this 
paradigm indicates a smaller shift in respective ED50 values for UMB 425 as compared to 
morphine for both the tail-flick (1.3-/6.4-fold) and hot plate (3.0-/7.8-fold) assays, effectively 
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1.1. Pain Management 
 Pain management is an ever-changing field, such that effective pharmacotherapeutic 
intervention is different from one patient to the next. While the definition of pain is continuously 
debated, an all-encompassing definition stems from the International Association for the Study 
of Pain Committee on Taxonomy, which defines pain as “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage,” where furthermore, “Pain is always subjective. Each individual learns the application 
of the word through experience related to injury in real life (1).”  
 1.1.1. Pain Terminology. Pain is an elaborate pathological condition(s) that can be 
categorized based on the manifestation of symptoms. Acute pain persists up until noxious 
stimuli are removed or until the underlying pathological condition subsides (2). On the contrary, 
chronic pain persists for an extended period of time and is defined as “pain that extends beyond 
the expected period of healing (3).” These definitions of pain are overly simplified; more focused 
terminology addresses the array of pain sensations felt in these conditions. Nociceptive pain 
occurs as a result of nociceptor stimulation and is categorized as visceral, deep somatic or 
superficial somatic pain. Visceral pain is diffuse, dull and difficult to localize (4). Deep somatic 
pain is a result of sprains and broken bones that activate nociceptors in muscles, bones and/or 
joints (5). Superficial somatic pain is induced by nociceptors in the skin and is sharp and 
localized (6). Neuropathic pain is persistent and is a result of malfunction to the nervous system 
leading to a loss of sensation or paraesthesic and dysesthesic sensations that are abnormal 
and uncomfortable (7). Phantom pain sensations stem from an absent limb whether by 
amputation or congenital limb deficiency (8). 
1.1.2. WHO Pain Assessment. The World Health Organization (WHO) was the first to 
develop a set of guidelines for the use of drugs for pain management. Medical care providers 
assess and treat patient pain using a wide array of agents ranging from non-opioid drugs with 
low side-effect liabilities to potent opioid narcotics. Paracetamol and non-steroidal anti-
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inflammatory agents (NSAIDs) are traditionally used for the treatment of mild pain and induce 
their effects via cyclooxygenase (COX) enzymatic inhibition, thereby reducing prostaglandin 
inflammatory mediator production. However, these drugs lack the efficacy to be used solely in 
more severe pain states. Opioid narcotics encompass a wide variety of drugs used to treat 
moderate-to-severe pain, including the well-known drug morphine. Opioid narcotics are 
prescribed as a stand-alone or in combination with non-opioids (i.e. Percocet, Vicodin). These 
commercial formulations are readily available and are intended to reduce opioid-related side 
effects while providing ample pain-relief or “analgesia”. The analgesic effect is a result of 
decreased pain perception, decreased pain reaction and/or increased pain tolerance. In 
addition, extended release formulations of opioid analgesics are readily available and designed 
to minimize tampering and misuse (9).  
1.1.3. Adjuvants for Pain Management. Adjuvants are drugs that do not traditionally 
produce analgesia on their own, but produce synergistic effects when given in combination with 
analgesic agents. Adjuvants are prescribed during treatment as recommended by the medical 
care provider. Steroids (10), antidepressants (11), anti-arrhythmics (12), anti-convulsants (13), 
local anesthetics (13), anti-cholinergics (14), muscle relaxants (15) and α2 agonists (16) are 
adjuvant agents used for various pain states and are potential alternatives to opioid narcotics in 
certain conditions of chronic pain. In addition, the use of cannabinoids has also emerged as an 
attractive, albeit controversial, alternative to opioids (17). Unfortunately, adjuvants themselves 
are not without their share of side effects and concerns (18). As such, opioid narcotics continue 
to be the traditional standards for individuals suffering from cancer pain, post-operative pain or 
pain from other severe trauma (19, 20). Opioid narcotics induce a wide range of analgesic 






1.2. Opioid Narcotics 
Opioid narcotics encompass a wide variety of psychoactive chemicals whose primary 
effects are induced through the central nervous system. The natural extract from the poppy 
plant papaver somniferum “opium” has been used therapeutically as far back as 2nd century 
Greece. Opium alkaloids isolated from the poppy plant are known as “opiates”. Alkaloids include 
morphine, codeine, thebaine and other minor alkaloids. The term “opioid” refers to opioid 
narcotics that are at least part synthetic and are not found in nature. Opioid narcotics have long 
been associated with the treatment of moderate-to-severe pain, ranging from acute post-
operative pain to long-term chronic pain of cancer patients. The most common physiological 
effects associated with opioid use include: sedation, dizziness, nausea, vomiting, constipation, 
physical dependence, tolerance and respiratory depression, while less common physiological 
effects include: hyperalgesia, immunologic and hormonal dysfunction, muscle rigidity and 
myoclonus (21).  
1.2.1. Opioid Chemical Classifications. Opioid narcotics can be broken down into four 
classes (Figure 1.1): (i) phenanthrenes, (ii) benzomorphans, (iii) phenylpiperidines and (iv) 
diphenylheptanes (22). Phenanthrenes are considered the standard opioids and depict the 
classical opioid pharmacophore; this class is composed of strong agonists and includes 
morphine, codeine, hydromorphone and oxymorphone among others. The prototypical 
benzomorphan opioid is pentazocine, which exhibits mixed agonist/antagonist effects and 
produces undesirable dysphoric effects. Phenylpiperidine opioids include the strong agonist 
fentanyl and subsequent derivatives. The primary opioid in the diphenylheptane class is the 
agonist methadone. Lastly, tramadol is a unique opioid narcotic that does not fit into any of the 
four standard opioid classes and also been shown to interact with γ-aminobutyric acid (GABA), 





Table 1.1. Opioid narcotic chemical classifications . 












Other than as an analgesic agent, opioids are prescribed for several other clinical 
indications. Dextromethorphan is an active ingredient common in many over-the-counter 
antitussive or “cough suppressing” drugs. Loperamide acts within the myenteric plexus of the 
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large intestine to treat diarrhea. Buprenorphine and methadone are both indicated for the 
treatment of opioid dependence. 
1.2.2. Opioid Pharmacokinetics. Opioid narcotics can be administered through numerous 
routes. The route of administration is largely responsible for onset of effect as well as the overall 
duration of action (24). The oral route of administration is most convenience for the patient. Oral 
preparations of the gold standard morphine result in lower rates of bioavailability due in part to 
presystemic metabolism but offers a longer duration of action than other routes of administration 
(25). Opioids that are highly lipophilic can be administered via intranasal, transdermal, 
sublingual routes of administration or even as a suppository (26). Additional routes of 
administration (i.e. subcutaneous, intramuscular, intrathecal) can prolong and produce 
heightened analgesic responses, but are inconveniently more invasive (26). Intravenous 
preparations of morphine act almost immediately, but do not readily cross the blood-brain-
barrier like that of more lipohilic agents, including heroin (25).  
Opioid narcotics are typically metabolized through phase I cytochrome p450 (CYP450) 
and phase II glucoronidation processes. Morphine undergoes phase II UDP-
Glucuronosyltransferase-2B7 (UGT2B7) metabolism (27) yielding it’s two major metabolites, 
morphine-6-glucoronide and morphine-3-glucoronide, both of which are readily able to cross the 
blood-brain barrier (BBB) (25). Morphine-6-glucoronide is highly efficacious and more potent 
than morphine itself, thereby contributing to the overall analgesic activity of morphine (28). 
Morphine-3-glucoronide does not induce analgesia (29). The half-life (t1/2) of morphine is 
typically 2-3 hours, but can vary depending on the experimental factors and individual patients 
(30). 
  1.2.3. Clinical implications of opioid narcotics. Long term opioid pharmacotherapy 
continues to rise; the United States utilizes over 80% of the world’s supply of opioids, including 
99% of the hydrocodone supply (31). Regrettably, the incidental death rate also continues to 
rise, where increasing dosing regimens has led to increased cases of accidental overdose (32). 
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Opioid intoxication is marked not only by respiratory depression but also drowsiness, euphoria 
and miosis (33). In cases of accidental overdose, opioid induced anoxia can result in death in as 
little as 1-3 hours (34). The therapeutically limiting side effects leave primary care physicians 
uneasy of their use as governing bodies are becoming increasingly circumspect (35-38). 
Unfortunately, this often leads to the undertreatment of patient pain (21). The subsequent 
consequences are costly as lost productivity is estimated to be greater than $60 billion annually 
for active workers with pain (39). Adequate pre-surgical analgesia has been shown to decrease 
post-operative pain and recovery time (40). Furthermore, the overall well being of the patient is 
also at risk with so called “analgesic gaps” that arise during post-operative pain management 
(41).  
Side effect liabilities can progressively worsen with the development of tolerance. 
Opioid-induced tolerance decreases drug potency, which is detrimental to patients as the 
discomfort from side effect liabilities outweighs reduced pain relief (42). Tolerance increases the 
risks of physical and psychological dependency, such that an individual can become addicted to 
their use and undergo withdrawal upon their discontinuation. Among psychotherapeutic drugs, 
opioid narcotics have the highest prevalence of abuse and dependence (43).  A balance needs 
to be achieved that allows access to opioid narcotics for proper use while incorporating 
strategies to prevent potential misuse. As such, a novel opioid analgesic with reduced tolerance 
liabilities could potentially alleviate many of the concerns associated with opioid narcotic use, 
leading to reduced health care costs as well as provide increased economic and health benefits. 
1.3. Opioid Receptors  
Opioid receptors are seven transmembrane G-protein coupled receptors (44) located in 
the central nervous system, peripheral nervous system and gastrointestinal tract (45). They 
belong to the class A4 subfamily of seven transmembrane (7TM) G-protein coupled receptors 
(GPCRs) (46), coupling to heterotrimeric guanine nucleotide binding proteins (G-proteins), most 
notably pertussis-toxin sensitive Gi/Go proteins (44), but also Gs (47, 48) and pertussis-toxin 
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insensitive Gz proteins (49). In 1973, an opiate receptor was first identified using radioligand 
binding techniques (50). To date three classical opioid receptor subtypes have been identified: 
mu (µ) (51), delta (δ) (52) and kappa (κ) (53). The three receptor subtypes are located 
throughout the nervous system, in somatic and visceral sensory neurons, spinal cord 
projections and interneurons (45). Genes encoding each of the three opioid receptor subtypes 
have been isolated and are known as Oprm, Oprd1 and Oprk1 for the µ, δ and κ receptor 
subtypes, respectively (54). Genetic polymorphisms of human opioid receptor genes can alter 
analgesic activity as well as tolerance and dependence liabilities (55). The three classic receptor 
subtypes display ~60% amino acid sequence identity (44, 56). The greatest homology is seen 
within the transmembrane helices and the most diversity is seen within the respective N- and C-
termini as well as the extracellular loops (56). Each receptor subtype also includes several 
characterized variants (µ1-3, δ1-2, κ1-3) that are believed to develop during post-translational 
interactions with accessory proteins as well as the formation of opioid receptor complexes (57-
61). Opioid receptor subtype variants are suggested to play similar roles in pain modulation and 
antinociception within that specific receptor subtype (62). Exogenous opioids induce their effects 
by mimicking endogenous opioid peptides.  
1.3.1. Endogenous Opioid Peptides. The three well-characterized families of 
endogenous opioid peptides are the endorphins, enkephalins and dynorphins, which are 
primarily selective for the µ, δ and κ receptor subtypes, respectively (63). All opioid peptides 
share a common N-terminal amino acid motif Tyrosine-Glycine-Glycine-Phenylalanine-
Methionine/Leucine (Tyr-Gly-Gly-Phe-Met/Leu) (64). The aromatic “A” ring of the traditional 
opioid pharmacophore is believed to mimic the Tyr residue that begin each opioid receptor 
peptide sequence (65). C-terminal extensions of this motif are unique for opioid peptides, 
ranging from 5 to 31 residues (57). Anatomical regions associated with nociception (e.g. the 
spinal cord, thalamus, periaqueductal gray, midbrain, limbic system and cortex) all contain 
neurons containing endogenous opioid peptides (62). Each of the three families is derived from 
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distinct precursor proteins, termed proopiomelanocortin (POMC), proenkephalin (PENK) and 
prodynorphin (PDYN) respectively, each of which is encoded by their corresponding gene.  
POMC undergoes post-translational modifications resulting in different biologically active 
endorphins, including the µ-selective ligand β-endorphin (66). Endorphins regulate physiological 
responses to stress and pain, producing analgesia as well as a state of well being (67). 
Endomorphins (i.e. endomorphin-1, endomorphin-2) are endogenous opioid tetrapeptides that 
also have high affinity for the µ receptor subtype (68). Unlike endorphins, endomorphins have 
not yet been linked as cleavage products to a larger precursor protein. Both have been shown 
to produce antinociceptive or “pain-relieving” effects (68). Furthermore, endomorphin-1 is 
thought to regulate sedation and arousal behaviors (69).    
The PENK gene has similar structural organization to the human POMC gene (70). Post-
translational modifications result in the formation of the δ-selective pentapeptides met-
enkephalin and, to a lesser extent, leu-enkephalin (71), located in both central and peripheral 
nervous system regions (72). Enkephalins have vital regulatory roles associated with pain 
perception, anxiety as well as aggression (73).  
PDYN post-translational modifications produce κ-selective dynorphins, specifically 
dynorphin A, dynorphin B and α/β neoendorphins (74). Primary dynorphin-induced effects 
concern the stress responses of analgesia, dysphoria and anxiety (75).  
Genetic targeting has furthered research in vivo, as mice lacking the respective receptor 
subtypes and endogenous peptides have uncovered the physiological functionalities of opioid 
receptors. Mice that are µ receptor subtype deficient have shown complete reductions in 
physiological responses to morphine, including: analgesia, reward, withdrawal, respiratory 
depression, constipation, hyperlocomotion and immunosupression (76, 77). However, µ 
receptor subtype deficient mice treated with δ agonists also demonstrated reduced 
antinociceptive capabilities compared to wild-type mice, suggesting cross-interactions between 
the µ and δ receptor subtypes (78, 79). As expected, δ receptor subtype deficient mice failed to 
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maintain antinociceptive properties when treated with δ agonists (80). κ receptor subtype 
deficient mice confirm the critical role of the receptor in visceral pain perception, antinociception, 
hypolocomotion and dysphoria (81).  
1.3.3. Nociceptin Receptor. The nociceptin receptor (NOP-R) is sometimes classified as 
the fourth opioid receptor, whose endogenous peptide is known as nociceptin/orphanin FQ (82, 
83) and is encoded by the OPRL1 gene (84). Nociceptin is derived from the pronociceptin 
protein (85). NOP-R shares ~60% sequence homology with the three classical opioid receptor 
subtypes (86). However, NOP-R does not exhibit binding affinity for traditional opioid ligands like 
that of the three classical subtypes (44). Furthermore, the peptide nociceptin does not act at the 
traditional opioid receptor subtypes nor are its actions antagonized by the non-selective opioid 
antagonist naloxone (87). While NOP-R activity is linked to nociception (88), the NOP-R has 
been shown to induce some differing physiological responses to that of the classical opioid 
receptor subtypes (86). Furthermore, nociceptin-induced effects have also been linked to opioid-
induced hyperalgesia (89). 
1.4. Opioid Mechanism of Action 
 Opioid analgesic activity is primarily associated with the activation of µ receptors located 
within the central nervous system (77). Specifically, spinal and supraspinal analgesia are 
induced through ascending and descending pathways (90). Nervous system regions involved in 
pain transmission include nociceptor fibers, the spinal cord, the midbrain and the thalamus (62). 
Nociception is “the neural processes of encoding and processing noxious stimuli,” (91) noxious 
stimuli being of thermal, chemical and/or mechanical means detected by sensory nociceptor 
fibers (92). Families of ion channel transducers (i.e. transient receptor potential (TRP) channel, 
acid-sensing ion channel (ASIC)) respond to noxious stimuli by activating voltage-dependent 
sodium (Na+) channels and initiating action potentials through nociceptor fibers projected to the 
dorsal horn of the spinal cord (92). There are two types of nociceptor fibers imperative in pain 
transmission signaling to the dorsal horn of the spinal cord; thinly myelinated Aδ-fibers sense 
21 
 
the initial quick and shallow first pain and unmyelinated C-fibers that respond slowly to non-
specified high intensity stimuli (93).  
1.4.1. Spinal Analgesia. Opioids induce spinal analgesia by activating pre-synaptic and 
post-synaptic opioid receptors resulting in decreased ascending neurotransmitter signaling from 
peripheral afferent fibers. Pre-synaptic activation of the classical opioid receptor subtypes 
decreases calcium (Ca2+) influx, which in turn decreases pain-modulating neurotransmitter 
release into the synapse of the dorsal horn of the spinal cord. Post-synaptic activation of µ 
receptors alters potassium (K+) channel conduction creating an inhibitory postsynaptic potential 
(IPSP) and ultimately depressing neuronal transmission. These neurotransmitters include 
tachykinin, substance P, glutamate and calcitonin gene-related peptide (CGRP) (94, 95). Other 
chemicals released at the site of injury include amines (e.g. histamine and serotonin) and 
excitatory amino acids (e.g. glutamate and aspartate) (96). Increased levels of prostaglandin 
inflammatory mediators enhance pain sensations (96). 
1.4.2. Supraspinal Analgesia. At the supraspinal level, analgesic effects are mediated by 
the activation of serotonergic and noradrenergic systems. Specifically, µ opioid receptor 
activation results in the disinhibition of GABA conitaining neurons synapsing on serotonin (5-HT) 
and norepinephrine (NE) neuronal pathways (90, 97). µ receptor activation decreases Na+ and 
Ca2+ influx and inhibits GABA neurotransmitter release. This prevents GABA-mediated inhibition 
upon descending 5-HT and NE containing neurons. Increased 5-HT and NE neurotransmitter 
release decreases pain sensation via descending pain transmission that terminates in the dorsal 
horn of the spinal cord. 
1.4.3. Cellular Responses to Opioids. As mentioned, opioid receptors are GPCRs that 
primarily induce their effects through the recruitment of pertussis toxin-sensitive Gi/Go proteins. 
At the cellular level, opioid agonist binding results in the activation of a heterotrimeric G-protein 
complex consisting of a Gα-guanosine diphosphate (GDP) and a Gβγ subcomplex. GDP bound 
to the Gα subcomplex is replaced by guanosine triphosphate (GTP), thereby forcing a 
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dissociation of both the Gα and Gβγ subcomplexes. Both the Gα and Gβγ subcomplexes mediate 
second messenger and effector activity. Finally, GTPase activity, where GTP is hydrolyzed to 
GDP, enables the reassociation of the Gα and Gβγ subcomplexes with the GPCR. GTPase 
activity is be modulated by regulators of G-protein signaling (RGS proteins) that can influence 
the exchange of GTP for GDP bound to the Gα subcomplex (98).  
Traditional responses of second messengers and effectors are associated with the 
inhibition of vesicular neurotransmitter release and signaling due to the inhibition of adenylate 
cyclase (AC), the inhibition of Ca2+ influx through voltage sensitive N-type channels and the 
activation of G-protein gated inwardly rectifying potassium channels (GIRKs) (99). Additional 
studies have linked opioid-induced effects via the activation of protein kinase C (PKC) (100) and 
the mitogen-activated protein kinase (MAPK) cascade (99), as well as the release of Ca2+ ions 
from internal stores (101). These effects can direct transcription factor pathways and influence 
signaling stemming from the plasma membrane to the nucleus (102).  
1.5. Opioid Induced Tolerance 
 The mechanisms regarding opioid induced tolerance remain elusive with no clinically 
viable therapeutic agent shown to prevent it. In terms of opioid narcotic use, tolerance requires 
escalating dosages to provide adequate pain relief. In turn, susceptibility to additional opioid-
induced side effects markedly increases. Several hypotheses have been drawn as to the 
underlying components of tolerance. 
 1.5.1. Role of Receptor Internalization. Upon receptor activation, opioid receptors 
traditionally undergo regulatory mechanisms including receptor desensitization, internalization, 
down-regulation and resensitization processes through receptor phosphorylation via GPCR 
kinases (GRKs) and the recruitment of β-arrestins, clathrin and other adapter proteins (103). 
Simply, the phosphorylated GPCR is bound to β-arrestin cytosolic proteins that uncouple the 
receptor from its respective G-protein and signal for clathrin-coated receptor internalization 
(104). Upon proper internalization, the receptor can become resensitized and return to the 
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cellular surface for further activation. Partial µ agonists, including morphine, are unable to 
properly replicate receptor internalizing mechanisms upon prolonged exposure (105, 106). The 
resulting effect is an uncoupling of the G-protein from the receptor, leading to receptor 
desensitization, or reduced responsiveness, of signaling mechanisms (103). Other µ agonist 
classes and their respective compounds have demonstrated variations in this initial hypothesis, 
where tolerance develops from multiple points within the endocytotic machinery (107). For 
example, the highly efficacious µ agonist etorphine undergoes proper internalization 
mechanisms upon chronic exposure, but instead induces tolerance through excessive 
downregulation of µ receptors (108). 
1.5.2. Adenylate Cyclase Superactivation. AC superactivation is another highly popular 
mechanistic theory surrounding opioid-induced tolerance (109). As described above, opioid 
receptors are members of the Gi/Go superfamily of GPCRs that inhibit AC. Research suggests 
that prolonged exposure to µ agonists, including morphine, results in adaptive changes 
promoting upregulation of the AC pathway (110, 111). This leads to increased concentrations of 
cyclic adenosine monophosphate (cAMP), thereby leading to protein kinase A (PKA) and, 
subsequently, cAMP response element-binding protein (CREB) activation (112-116). Elevated 
cAMP levels are responsible for alterations in gene expression as well as neurotransmitter 
release (109, 117). The mechanisms surrounding these upregulations are still not clear, though 
may include modified protein phosphorylation (47, 118), receptor coupling to the Gs family of G-
proteins (119, 120), involvement of the Gβγ subcomplex (121) or possible upregulation in 
constitutive receptor activity (122-124). It is clear that AC superactivation can lead to potential 
transcriptional changes involved in long-term regulation of other proteins involved in cell 
function. 
1.5.3. P-glycoprotein Upregulation. P-glycoprotein (P-gp), a member of the ATP binding 
cassette (ABC1) family, is an efflux transporter that has been implicated in opioid-induced 
tolerance (125, 126). P-gp expression is noted within the BBB, with the purpose of maintaining 
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the integrity of the central nervous system (CNS). P-gp has been shown to influence the 
pharmacokinetic and pharmacodynamic profiles of drugs that are substrates of this transporter 
(127). Several opioid analgesics, including morphine and oxycodone, have been classified as P-
gp substrates that upregulate P-gp expression levels upon chronic administration, thereby 
reducing antinociceptive effects. Current studies look to further identify P-gp invovlement in 
opioid-induced tolerance by synthesizing novel opioid compounds with reduced P-gp 
interactions (128-130). 
1.6. Mu/Delta Opioid Receptor Interactions 
Evidence suggests that opioid narcotics may induce their physiological effects through 
dimeric and oligomeric complexes formed from the opioid receptor subtypes. Specifically, the µ 
and δ receptor subtypes have been shown to exist as hetero-dimeric (131) as well as hetero-
oligomeric complexes (132, 133). It is known that δ receptor activation produces minimal 
analgesic activity on its own (134). However, the physiological association between the µ and δ 
receptor subtypes has been shown to improve ligand binding at each subtype through allosteric 
modulation (135), leading to enhanced analgesic effects (136). In addition, both the µ and δ 
receptor subtypes have been shown to exist on similar neuron populations, such that cell 
signaling through one receptor subtype is influenced by activation of the other (137).  
1.6.1. Joint µ and δ Opioid Receptor Subtype Studies. Synergistic analgesic effects have 
been reported when δ-selective agonists are given in conjunction with traditional µ agonists 
(138). Unfortunately, it is believed that simultaneous δ receptor activation with that of the µ 
receptor may play a role in the side effect liabilities associated with chronic opioid use, including 
tolerance (139). Further exploration has shown that δ-selective antagonists given in conjunction 
with µ agonists, including morphine, can elicit potent analgesic properties whilst reducing 
tolerance liabilities (139, 140). In addition, low doses of the non-selective opioid antagonist 
naloxone have been shown to retain or potentiate analgesia while attenuating tolerance and 
dependence liabilities (141, 142), by antagonizing Gs protein induced excitatory functions (143). 
25 
 
These results have been further confirmed by δ receptor knockout (144) and antisense 
oligonucleotide studies (145-147). These findings suggest that opioid ligands depicting dual 
effects of µ agonism and δ antagonism can be effective for patients whom require chronic opioid 
pain management such that adequate analgesia is achieved with reduced tolerance liabilities.    
1.6.2. Mixed µ Agonist/ δ Antagonist Opioid Ligands. Opioid peptides depicting dual 
effects of µ agonism and δ antagonism have been synthesized in order to help pinpoint the 
optimal structural and conformational features needed for binding affinity and functional activity 
at the selected receptor subtypes (148, 149). Several designs have been successful in 
identifying such peptides, including those that have reduced tolerance liabilities compared to 
traditional opioid analgesics (150). While useful as research tools, opioid peptides are not 
clinically viable options for universal human use.  
A single opioid agent depicting mixed µ agonism/δ antagonism is more advantageous for 
clinical use than relying on patient compliance with multiple drugs. The identification of non-
peptidic opioid analgesics which display these properties could convey therapeutic advantages 
compared to peptides, with regards to ease of administration and delayed metabolic breakdown. 
Several approaches towards this goal have been undertaken, specifically the characterization of 
bivalent and bifunctional opioid ligands. Portoghese et al. introduced the concept of bivalent 
ligands, compounds that embody two specific pharmacophores connected via an optimized 
linker (151). Bivalent ligands containing both selective µ agonist and δ antagonist derived 
pharmacophores have been shown to exhibit greater analgesic effects, while also reducing 
tolerance and physical dependence liabilities (152). As previously discussed, the existence of 
hetero-oligomeric opioid receptor complexes, including a µ-δ complex (132), suggests that 
bivalent opioid ligands are a viable therapeutic tool. However, the physiochemical properties of 
bivalent ligands may prove problematic with regards to an oral absorption formulation (153).  
Bifunctional ligands are based on a single pharmacophore that encompass two binding 
sites with functional activity distinct for each of the respective sites (154). This approach ideally 
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circumvents potential problematic characteristics pertaining to bivalent ligands. Bifunctional 
ligands include structural moieties seen in traditional µ agonists as well as δ antagonists. 
Ligands depicting mixed µ agonism/δ antagonism functionalities have displayed potent 
analgesic activity with reduced side effect liabilities, including tolerance (155, 156). Previously 
developed bifunctional ligands explore series of pyridomorphinan and pyrrolomorphinan 
frameworks derived from non-selective antagonists (i.e. naloxone) as well as highly efficacious 
µ agonists (i.e. oxymorphone and hydromorphone) (157). However, those developed are 
traditionally characterized in vivo by intracerebroventricular administration, a method unsuitable 
for wide spread therapeutic use. Therefore, in vivo studies need to be performed using less 
invasive methods that can effectively corroborate reduced tolerance liabilities seen via 
intracerebroventricular administration.  
1.7. Objectives 
While moderate-to-severe pain management has relied on the use of opioid narcotics, 
the therapeutically limiting side effects associated with their use remain controversial and has 
led to the undertreatment of patients. For the past few decades opioid narcotics have been 
prescribed more readily. However, incidental deaths have risen with increasing dosing 
regimens. This suggests that opioid-induced tolerance is of major clinical concern, whereby 
increased use can exacerbate side effect liabilities. 
Opioid-induced analgesia is primarily induced through the activation of µ receptors 
located within the CNS. It has been shown that δ antagonists given in conjunction with 
traditional µ agonists can maintain potent analgesic properties while reducing the side effect 
liabilities, specifically tolerance. Our hypothesis is that a novel compound displaying dual 
properties of µ agonism and δ antagonism can be created to provide potent analge sic 
relief with reduced tolerance liabilities.  
A single compound that demonstrates dual effects of µ agonism and δ antagonism has 
several practical clinical advantages over the co-administration of a traditional µ agonist (i.e. 
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morphine) and a δ antagonist. Patient compliance is always of concern, such that the 
administration of one is drug is preferred over two drugs. A multicomponent drug regimen can 
prove problematic if not taken as prescribed, resulting in less than optimal therapeutic levels 
and poor treatment outcomes (153). Furthermore, it has been shown that antagonism at the δ 
receptor must occur simultaneously with agonism at the µ receptor in order to prevent tolerance 
development (158). Finally, the abuse liability of traditional µ agonists can be troublesome, as 
patients can divert from their therapeutic intent (159). As a result, compounds depicting mixed µ 
agonist/δ antagonist properties are anticipated to possess reduced abuse liabilities.  
Novel UMB opioid ligands have been synthesized by our collaborators at the University 
of Maryland-Baltimore, under the tutelage of Dr. Andrew Coop. To test our hypothesis, the 
following specific aims will be addressed: 
1. To confirm targeted receptor binding affinities and functionalities of novel UMB opioid 
ligands in vitro (Chapter 2). Novel UMB opioid ligands were synthetically designed with the 
intentions of demonstrating agonistic effects through the µ receptor, whilst having antagonistic 
effects through the δ receptor. Confomationally Sampled Pharmacophore (CSP) modeling 
studies will be utilized to predict ligand functionality at the three receptor subtypes. Binding 
affinities will be tested at each of the three receptor subtypes using radioligand binding assays. 
[35S]guanosine 5'-O-[gamma-thio]triphosphate (GTPγS) functional assays will be performed to 
determine the agonistic/antagonistic properties of UMB opioid ligands for the three receptor 
subtypes. 
2. To demonstrate antinociceptive effects of novel UMB opioid ligands in vivo (Chapter 
3). The acute antinociceptive effects of novel UMB opioid ligands will be determined using tail-
flick and hot plate thermal nociceptive assays. Antagonist pre-treatment studies will be 
performed to ensure that the acute effects are induced through opioid mechanisms.  
3. To demonstrate reduced tolerance liabilities of novel UMB opioid ligands in vivo 
(Chapter 4). Mice will undergo a chronic UMB opioid ligand administration regimen to determine 
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tolerance development. It is anticipated that the level of UMB opioid ligand induced chronic 
tolerance will be significantly less than that of morphine itself.  
The primary goal of this study is to develop at least one UMB opioid ligand that 
maintains potent antinociceptive properties while reducing the side effect liabilities associated 
with chronic opioid use, specifically tolerance. In addition, the studies herein will further advance 
opioid structure activity relationships (SAR), specifically those of mixed µ/δ activity, with respect 
to the chemical structure modifications and the subsequent pharmacological profiles. 
1.8. Contributions 
All compounds, including UMB 425, were synthesized by the laboratory of Dr. Andrew 
Coop at the University Of Maryland School Of Pharmacy in Baltimore, Maryland. 























2.1. Introduction  
The synthetic design rationale for mixed µ agonist/δ antagonist opioid ligands stems 
from the message-address concept first proposed by Robert Schwyzer with regards to 
adrenocorticotrophic hormones (160) and later adapted by Portoghese and colleagues for the 
development of non-peptidic opioid ligands (65). Endogenous opioid peptides all share the 
same tetrapeptide amino acid sequence (Tyr-Gly-Gly-Phe) that can be viewed as the “message” 
sequence; the message sequence is involved in receptor affinity and downstream signaling. The 
remaining amino acid sequences of endogenous opioid peptides are viewed as “address” 
sequences, which provide selectivity as well as additional binding affinity. This concept allows 
for the design of opioid receptor subtype specific ligands, the δ-selective antagonist naltrindole 
one of the first. Naltrindole incorporates an indole functional group fused to the “C” ring of the 
non-selective opioid antagonist naltrexone, in turn mimicking the δ-selective opioid peptide 
enkephalin. Thus, the message-address concept introduced conceptual frameworks that 
enabled researchers to design ligands that could effectively manipulate interactions at the 
specific opioid receptor subtypes.  
Traditional opioid SAR focuses on substituents at one position of the opioid skeleton 
which allows for the formation of predictive models. Unfortunately, further studies utilize 
additional substituents at other positions on the opioid skeleton which typically negates previous 
SAR. Thus, consensus pharmacophore models of opioid ligands at the receptor subtypes 
remain elusive. However, CSP modeling studies utilize all possible structural configurations 
between critical functional groups, termed “pharmacophoric descriptors”, of opioid ligands in 
order to create representative pharmacophoric models at each of the opioid receptor subtypes 
(161). Previous opioid SAR models were traditionally used to predict binding affinities. CSP 
models are unique in that they utilize functional data from known ligands to best predict efficacy 
values, thereby predicting the agonistic and antagonistic properties of novel opioid ligands at 
each of the opioid receptor subtypes. CSP modeling takes into account all geometric angles and 
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distances between pharmacophoric descriptors, with the consideration that the most stable low-
energy structural configuration of a ligand may not occur upon receptor binding (162-164). CSP 
models for µ receptor ligands employ the aromatic “A” ring, basic nitrogen, N-substituent and 
the “C” ring  hydrophobic substituent as the respective pharmacophoric descriptors; these 
functional groups are deemed the most significant for efficacy at the µ receptor (161).  
Pharmacophoric descriptors included in δ receptor CSP modeling are consistent with those of 
the µ receptor, with the exception of the N-substituent (165, 166).  
The design of ligands herein is unique and stems from a class of potent µ agonists, the 
orvinols (i.e. etorphine). In addition, the orvinols are also known to interact with the δ and κ 
receptor subtype, typically displaying agonism at the δ receptor subtype (167). It is 
hypothesized that efficacy at the δ receptor subtype can be minimized with the introduction of a 
benzene ring containing moieties seen in two classes of low efficacy δ-selective opioid ligands, 
specifically the indolomorphinans (e.g. naltrindole) (168) and the opioid benzylidenes (e.g. 
BNTX) (169). Furthermore, the orvinol series includes 6,14-bridged-morphinan based ligands, a 
structural moiety that can potentially be modified to influence functionality at the respective 
opioid receptor subtypes (170, 171). As such, specified ligands primarily are or are precursors 
to 5,14-bridged-morphinan based ligands with the intent of identifying a mixed µ agonist/δ 
antagonist opioid analgesic with reduced tolerance liabilities. 
For all pharmacological testing in vitro, Chinese Hamster Ovary (CHO) cells stably 
transfected with and overexpressing the three opioid receptor subtypes are used. The rationale 
for the use of immortalized cell lines, compared to primary tissue membrane, is to isolate 
receptor subtypes such that data obtained is specific for that subtype alone. Opioid receptor 
subtypes have been shown to form homo- as well as hetero-dimer (131) and –oligormeric (132, 
133) complexes which can influence binding and functionality. As such, it is plausible that the in 
vitro pharmacological profile may not parallel results obtained in vivo. However, past studies 
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have shown that pharmacological activity with the use of isolated cell lines correlate well with 
results seen in tissue membrane (172). 
Competition binding assays are initially performed in vitro to ensure desired interactions 
between novel compounds with specified receptors. These studies are performed in a recently 
adopted 96-well format; assay validation using conventional opioid ligands was performed prior 
to testing of novel ligands.  [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO), [D-Pen2,5]-
enkephalin (DPDPE) and U69,593 are synthetic subtype specific opioid ligands used as the 
positive and negative control standards for the µ, δ and κ receptor subtypes, respectively. 
Radioactive preparations of [3H]DAMGO, [3H]DPDPE and [3H]U69,593 are used as the “hot” 
ligand standards during competition binding assays for the µ, δ and κ receptor subtypes, 
respectively.  
[35S]GTPγS functional assays allow for the determination of the functionalities, or agonist 
and antagonistic properties, of GPCRs, a family that includes opioid receptors. DAMGO, 
DPDPE and U69,593 are all highly efficacious agonists and, consistent with previous studies, 
bookmarked as the 100% Emax standards for the µ, δ and κ receptor subtypes, respectively.  
Morphine and codeine were chosen as drug standards for competition binding and 
[35S]GTPγS functional assays performed in vitro, since they are two readily prescribed opioid 
narcotics used for pain management. Side-by-side comparisons of our novel compounds with 
commonly used analgesic agents will provide initial indications for potential clinical viability. In 
addition, the non-selective opioid antagonists, naloxone and naltrexone, are also used as drug 
standards. Naltrexone is used to validate antagonistic effects in [35S]GTPγS functional assay 
preparation.  
2.2. Methods 
2.2.1. Competition Binding Assays. Chinese hamster ovary (CHO) cells were stably 
transfected with and overexpress the human µ opioid receptor (hMOR-CHO), the human δ 
opioid receptor (hDOR-CHO) or the human κ opioid receptor (hKOR-CHO). Cells were grown in 
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150-mm dishes (Fisher Scientific, Hanover Park, IL) in DMEM supplemented with 10% FBS, 
penicillin-streptomycin and G418 at 37 0C in a 5% CO2 atmosphere. Specifically, DMEM:F12 
(1:1) with HEPES, L-Gln solution was used when preparing hMOR-CHO and DMEM 4.5 g/l 
glucose was used when preparing hDOR-CHO and hKOR-CHO. At 80-90% confluency, cells 
were scraped from dishes and centrifuged at 2200 RPM for 12 min at 4 0C. Cell pellets were 
resuspended in 50 mM Tris buffer, pH 7.7, and homogenized using a Polytron, then spun down 
twice more at 13500 RPM for 20 min at 4 0C. Membrane was suspended in 50 mM Tris buffer, 
pH 7.7, at protein concentrations of about 3 mg/mL for hMOR-CHO and hKOR-CHO and 4 
mg/mL for hDOR-CHO. Membranes were aliquoted into polypropylene tubes and frozen at -80 
0C for future use. Protein concentration was determined using BCA reagent and BSA protein 
standard provided by the manufacturer (Pierce, Rockford, IL).  
Membranes were incubated with 10-12 concentrations of drug (0.001-100,000 nM) and 
radiolabeled ligand in 50 mM Tris buffer, pH 7.7, at a final volume of 1 mL. µ receptors were 
labeled using 1.3 nM [3H]DAMGO. δ receptors were labeled using 1.2 nM [3H]DPDPE. κ 
receptors were labeled using 1.7 nM [3H]U69,593. Non-specific binding was determined using 
non-labeled equivalents at each receptor subtype: 10 µM DAMGO, 1 µM DPDPE and 10 µM 
U69,593. Each concentration was tested in triplicates of duplicates with a total volume of 1 mL 
for each well. Following a 60 min incubation period reactions were terminated via rapid vacuum 
filtration over Perkin Elmer Unifilter®-96, GF/B filters (Fisher Scientific, Hanover Park, IL) that 
were presoaked in 0.5% polyethyleneimine (173) for 30 min. After filtration, filters were washed 
three times with 1.5 mL of cold 50 mM Tris buffer, pH 7.7 and counted in 40 µL of Perkin Elmer 
Microscint 20 (Fisher Scientific, Hanover Park, IL). Mean Ki values ± S.E.M. were determined 
performing experiments in triplicates of duplicates and calculated using Kd values obtained 
during saturation binding assays and the Cheng-Prusoff equation (174). Respective Kd values 
are 2.3, 2.4 and 2.4 nM for the µ, δ and κ receptor subtypes, respectively.  
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2.2.2. [35S]GTPγS Functional Assays. Membrane preparation for [35S]GTPγS binding 
was similar to the aforementioned opioid binding studies, with the exception that CHO cells 
expressing hMOR, hDOR and hKOR were resuspended in a final solution (“Buffer A”) consisting 
of 100 mM NaCl, 10 mM MgCl2, 20 mM Hepes, pH 7.4. Membranes were incubated with 10-12 
concentrations of drug and 0.1 nM [35S]GTPγS in “Buffer A” at a final volume of 1 mL. Basal 
activity was determined in the presence of exogenous GDP (10 µM) in the absence of agonist; 
exogenous GDP is required for all samples, basal or otherwise, to suppress the unstimulated 
basal radioligand binding to the G-protein. Non-specific binding was determined in the presence 
of 10 µM unlabelled GTPγS. Following a 60 min incubation period, reactions were terminated 
via rapid vacuum filtration over Perkin Elmer Unifilter®-96, GF/B filters that were presoaked in a 
1% bovine serum albumin (BSA) solution for 30 min. After filtration, filters were washed three 
times with a total of 1.5 mL of cold 50 mM Tris buffer, pH 7.7 and counted in 40 µL/well of 
Perkin Elmer Microscint 20. Data are presented as the percentage of agonist stimulation 
(%Emax) of [
35S]GTPγS binding normalized against maximal stimulating concentrations of 10 µM 
DAMGO, 1 µM DPDPE or 10 µM U69,593. %Emax values were determined using the equation: 
[(CPMbound-CPMbasal)/(CPMmax-CPMbasal)] x 100. Antagonistic properties at δ were determined by 
constructing dose-response curves of DPDPE (0.01-1000 nM) in the presence and absence of 
naltrexone control, UMB 425 or UMB 426. Test compound concentrations were 1x, 3x, and 10x 
the estimated Ki value obtained from binding studies. pA2 values are indicative of antagonistic 
potency at a particular receptor subtype and were determined using a Schild plot, whereby the 
plot’s x-intercept equals pA2. Corresponding slope values at or near -1 indicate competitive 
antagonism for the compound at that particular receptor subtype. For compounds displaying 
%Emax < 50, potential antagonistic properties can be determined. Mean ± S.E.M. were 
determined by performing experiments in triplicates of duplicates. 
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2.2.3. Synthesis of UMB 425. The synthetic scheme for 4a,9-dihydroxy-7a-
(hydroxymethyl)-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin 
7(7aH)-one (UMB 425) is shown in Figure 2.1.  
Ethyl 7,9-dimethoxy-3-methyl-2,3,4,7a-tetrahydro-1 H-4,12-methanobenzofuro[3,2-e] 
isoquinoline-7a-carboxylate ( 178):  A solution of 1 (1g) in 20 mL of tetrahydrofuran (THF) was 
placed in a flame-dried round-bottom flask, and 1.92 mL (1.5equiv) of a 2.5 M solution of n-
butyllithium in hexane was added while stirring at -78 0C under nitrogen. The mixture 
immediately turned deep wine-red and was stirred for 45 min at -78 0C. 0.36 mL (1.2 equiv) of 
ethyl chloroformate was added and the mixture was stirred for 4 h at -78 0C. The color changed 
to orange-yellow. 5mL saturated NH4Cl was then added per drop and most part of the solvent 
was removed under reduced pressure. The residual brown product was dissolved in chloroform, 
washed with brine solution, dried (Na2SO4) and concentrated. The residue was subjected to 
column chromatography on silica gel using chloroform-methanol (95:5) as eluent to isolate 
0.786g (64% yield) of 2 as a yellow liquid (179). 
(7,9-dimethoxy-3-methyl-2,3,4,7a-tetrahydro-1 H-4,12-methanobenzofuro[3,2-
e]isoquinolin-7a-yl)methanol (3):  Lithium aluminum hydride (LAH) (0.00496g, 0.13 mmol) was 
added to a stirred solution of 2 (0.050g, 0.13 mmol) in dry THF (2 mL) at 0 0C and allowed to 
warm to room temperature. After 2 h quenching, saturated sodium sulfate was added to the 
reaction mixture and stirred for 30 min. The reaction mixture was filtered through celite; the 
organic layer was separated, concentrated and purified by silica gel column chromatography 
(15:85 methanol-chloroform) to yield the pure product 3 as a pale yellow solid (0.036g, 81% 
yield) with mp 169-171 oC (180). 
4a-hydroxy-7a-(hydroxymethyl)-9-methoxy-3-methyl-2, 3,4,4a-tetrahydro-1 H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7(7a H)-one (4):  An ice-cold mixture of 0.4 mL of 0.7% 
H2SO4, 0.125 mL of 88% HCO2H, and 0.251 mL of 30% H2O2 was added to 0.3g (0.879 mmol) 
of 3. The mixture was stirred at 0 0C until transparent (~30 min). The resulting solution was kept 
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for 70 h in a refrigerator (4 0C), then poured into 3 mL of ice water which was made alkaline by 
the addition of concentrated ammonia solution. The mixture was extracted with 5 portions of 
chloroform and the organic extracts were combined, dried over sodium sulfate, and evaporated 
to obtain 0.184 g (61%) of 4 as a white solid (181). 
4a-hydroxy-7a-(hydroxymethyl)-9-methoxy-3-methyl-2, 3,4,4a,5,6-hexahydro-1 H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7(7a H)-one (5):  To a solution of 4 (0.13g, 0.379 mmol) 
in 5 mL of 1:1 ethanol-glacial acetic acid was added Pd/C (10%, 15 mg). The mixture was 
evacuated and filled with H2 gas in a hydrogenation flask and maintained under 40 psi H2 
pressure for 4 h. The reaction mixture was filtered through celite, the solvent was evaporated 
and the residue was basified with aqueous ammonia prior to CHCl3 extraction. Organic phases 
were combined, washed with brine, dried over anhydrous Na2SO4 and solvent was evaporated. 
The residue was subjected to column chromatography (7:93 methanol-chloroform) to give 5 as 
white foam (0.0915 g, 70%). 
4a,9-dihydroxy-7a-(hydroxymethyl)-3-methyl-2,3,4,4a ,5,6-hexahydro-1 H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7(7a H)-one (UMB 425):  Compound 5 (0.104g, 0.3 
mmol) was dissolved in 2 mL CHCl3 and cooled to 0 
0C, followed by the slow addition of BBr3 
solution (1 M in CHCl3, 1.5 mL). The mixture was stirred at 0 
0C for 3 h, carefully quenched with 
ice and basified with ammonia solution. The resulting mixture was stirred for 30 min at 0 0C, the 
aqueous layer was separated and the aqueous phase was extracted with CHCl3 (3 x 10 mL). 
Organic phases were combined, washed with brine and dried over sodium sulfate and the 
solvent was evaporated. The residue was subjected to column chromatography (20:80 
methanol-dichloromethane) to obtain UMB 425 as an off-white solid (0.0638 g, 64%) with mp 





 Figure 2.1. Chemical synthesis of UMB 425 from the baine.  (a) n-BuLi, Ethyl chloroformate, THF, -78 oC, 4h, 64%; 
(b) LiAlH4, THF, 0 
oC - rt, 2h, 81%; (c) H2O2, HCOOH, H2SO4, 4 
oC, 70h, 61%; (d) 10% Pd/C, H2, 1:1 Ethanol-Glacial 
Acetic acid, 4h, 70%; (e) BBr3, CHCl3, -20 
oC, 3h, 64%. 
 
2.2.4. µ Agonism/δ Agonism Dual-Profile CSP Model. CSP models developed for µ 
(161) and δ (165, 166) receptor ligands were used for studies herein, with some modifications to 
the δ receptor model. Updating of the δ receptor model was performed prior to predictions of 
efficacy of UMB 425. As this study involved derivates of 4,5-epoxymorphinans, the training set 
was limited to small non-peptidic opioids: BW373U86, etorphine, SIOM (7-
spiroindanyloxymorphone), oxymorphindole, diprenorphine, buprenorphine, naltrexone, 
naltrindole and (E)-BNTX [(E)-benzylidenenaltrexone]. Figure 2.2 shows the chemical structure 
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of compounds used as the training set and their experimental efficacies measured in earlier 
reported [35S]GTPγS assays. For updating the δ receptor CSP model, the selected ligands were 
modeled using the CHARMM22/CMAP and CHARMM General Force Field (CGenFF) with 
Replica Exchange Molecular Dynamics (REX-MD) for conformational sampling, as previously 
described. Pharmacophoric descriptors were designated for calculations of distances and 
angles between varying functional groups and are identified as an aromatic ring (A), a basic 
nitrogen (N) and a hydrophobic group (B) (Figure 2.2). BW373U86 was used as the reference 
compound for model development. Statistical models were trained using both agonists and 
antagonists to differentiate overlapping patterns between the two classes of compounds as well 
as develop a model that allows for quantitative estimations of efficacy. Changes with respect to 
the original δ receptor model, include: 1) for BW373U86, the center of mass of the two 
piperazine nitrogen groups was designated the N pharmacophoric descriptor, and 2) 1D overlap 
coefficients with respect to the reference compound were used to obtain multiple regression 
models with two independent variables; tests using three independent variables did not lead to 




Figure 2.2. Compounds included in the δ receptor CSP training set.  Pharmacophoric descriptors are designated 
in colors where green represents an aromatic ring (A), blue a basic nitrogen (N) and red a hydrophobic group (B).  
 
Prediction of the efficacy of UMB 425 applied previously developed µ agonism (161) and 
δ agonism (165, 166) CSP models, with the latter updated to include a larger number of non-
peptidic opioid δ ligands. CSP updated δ model generation involved development of multiple 
individual models based on different pharmacophoric descriptors (Figure 2.2); the top five 
models of the updated δ CSP are listed in Table 2.1, each with an R2 greater than 0.89. The 
final CSP model is based on averaging the predicted efficacies from these top five models. 
From the model, overlap of the aromatic ring (A) to hydrophobic group (B) distance distributions 
was identified as the most important descriptor. AB distances of compounds showing agonism 
at δ opioid receptors had greater overlap with those of (±)-4-((α-R*)-α-((2S*,5R*)-4-allyl-2,5-
dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethyl-benzamide (BW373U86) than antagonists; 
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however, efficacy was explained not solely by the AB distance, but in combination with the 
relative position of the hydrophobic group with respect to the aromatic ring and basic N. 
Accordingly, overlap coefficients of angles ANB, BAN, and ABN were identified as important 
descriptors by the automated variable selection applied during model construction.  
 
Table 2.1.  Top five δ receptor conformationally sampled pharmacophore mo dels that define the final 
predictive model.  Multiple regression equations, efficacy = aX1 + bX2 + c. N represents the basic nitrogen, A is the 
aromatic ring and B is the hydrophobic group, as shown in Figure X. X1 and X2 are overlap integrals with respect to 
the reference compound, while a and b are coefficients for variables X1 and X2 and c is the y-intercept in the 
regression equations. R2 is the goodness of fit, p-value the significance of models and correlation coefficients 
between X1 and X2 overlap coefficients.  
 
Calculated efficacies for the training set molecules are shown in Table 2.2 together with 
experimental values reported previously (183). The model predicts buprenorphine to be a weak 
partial agonist at δ receptors due to its resemblance to etorphine, particularly with respect to the 
AB distances. Oxymorphindole and naltrindole were not differentiated by the model. The only 
difference between them is the N-substituent (N-methyl for oxymorphindole and N-
cyclopropylmethyl for naltrindole) and the present model did not include the N-substituent as a 
pharmacophoric descriptor because the length of the N-substituent is not as critical for the δ 
receptor as it is for the µ receptor. However, the weak partial agonism of oxymorphindole seems 













Model # a X1 b X2 c R
2 p-value Correlation Coefficient 
1 0.465 AB 0.514 BN 0.028 0.962 0.00005 0.815 
2 0.730 AB 0.235 ANB -0.031 0.919 0.00054 0.519 
3 0.760 AB 0.187 BAN -0.026 0.911 0.00071 0.442 
4 0.749 AB 0.182 ABN -0.037 0.893 0.00121 0.603 
5 1.094 BN -0.196 ANB 0.108 0.890 0.00133 0.797 
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 Relative %Emax 
Name Experimental Calculated 
BW373U86 1.00 0.96 
Etorphine 0.36 0.36 
SIOM 0.18 0.13 
Oxymorphindole 0.12 0.04 
Diprenorphine 0.08 0.01 
Buprenorphine 0.00 0.13 
Naltrexone 0.00 0.01 
Naltrindole 0.00 0.04 
(E)-BNTX 0.00 0.07 
 
Table 2.2.  Comparison between experimental and calculated effi cacy values for compounds in training set.  
Experimental data, except buprenorphine and naltrexone, is previously reported. Buprenorphine and naltrexone were 
experimentally designated %Emax = 0 values as both are classified as antagonists at the δ receptor. BW373U86 = (±)-
4-((α-R*)-α-((2S*,5R*)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethyl-benzamide, SIOM = 7-
spiroindanyloxymorphone, (E)-BNTX = [(E)-benzylidenenaltrexone].  
 
2.3. Results  
 2.3.1. Competition Binding Assays. Table 2.3 summarizes results of reference 
compounds for the validation of these assays. Compounds known to be active at each of the 
respective subtypes were confirmed to have significant affinities herein; compounds known to 
be active at other subtypes were confirmed to exhibit neglible displacement.  
Table 2.3. K i (nM) values of standard opioid compounds at variou s subtypes. 
 µ δ κ 
DAMGO 1.5 ± 0.37 >10,000 >10,000 
DPDPE 618 ± 64 2.4 ± 0.33 >10,000 
U69,593 >10,000 >10,000 1.1 ± 0.49 
Naltrexone  0.46 ± 0.12 11 ± 1.1 1.1 ± 0.06 
Naloxone  2.2 ± 0.09 44 ± 3.6 7.2 ± 0.24 
Morphine  1.7 ± 0.34 87 ± 6.6 69 ± 1.3 
Codeine  624 ± 8.9 >10,000 >10,000 
 
Affinities (Ki in nM) were determined in CHO cells transfected with and overexpressing the human opioid receptor 
subtypes. The values in this table represent the mean + S.E.M. from replicate assays performed in triplicate. Values 
of >10,000 signify that there was less than 50% displacement of the radioligand at that concentration. 
 
The average binding affinities in nM for UMB opioid ligands for the three opioid receptor 
subtypes are shown in Table 2.4. Classical opioid structure activity relationships were applied 
towards the development of bifunctional ligands using structural characteristics of µ agonism 
and δ antagonism. Therapeutically limiting side effects associated with κ receptor activation, 
specifically dysphoria (184) and potentially hyperalgesia (185), were undesirable; the overall 
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synthetic design was also geared towards minimal, if any interaction, with the κ receptor. As 
expected, compounds depicting δ-specific moieties (i.e. indole, benzylidene) fused to the C-ring 
of the opioid pharmacophore exhibited increased selectivity for the δ receptor to that of the µ 
receptor. Overall, compounds displayed high-to-moderate binding affinity for the µ and δ 
receptor subtypes, with moderate-to-poor affinity for the κ receptor subtype. However, within this 
group of compounds, no structural configuration trended towards increased affinity towards any 
of the opioid receptor subtypes.   
Table 2.4. Chemical structures and binding affiniti es (K is) of UMB opioid ligands. 
Structure Compound Name µ: K i (nM) δ: K i (nM) κ: K i (nM) 
 
UMB 246 18 ± 1.1 14 ± 0.65 1067 ± 39 
 
UMB 375 28 ± 0.90 2.0 ± 0.31 186 ± 2.0 
 
UMB 376 64 ± 2.9 2.9 ± 0.38 968 ± 85 
 




UMB 378 51 ± 3.8 10 ± 1.6 525 ± 22 
 
UMB 405 23 ± 1.8 207 ± 11 806 ± 25 
 
UMB 406 154 ± 12 13 ± 0.51 15 ± 0.69 
 
UMB 407 >10,000 181 ± 7.1 >10,000 
 
UMB 425 3.2 ± 0.14 208 ± 18 212 ± 21 
 










UMB 427 717 ± 48 353 ± 79 >10,000 
 
UMB 437 17 ± 1.5 201 ± 16 1040 ± 29 
 
UMB 438 179 ± 17 73 ± 8 4153 ± 158 
 
UMB 439 300 ± 29 184 ±13 2429 ± 176 
 




UMB 441 313 ± 23 168 ± 9.2 793 ± 58 
 
UMB 449 2.1 ± 0.13 50 ± 4.9 107 ± 10 
 
Affinities (Ki in nM) were determined in CHO cells transfected with and overexpressing the human opioid receptor 
subtypes. The values in this table represent the mean + S.E.M. from replicate assays performed in triplicate. Values 
of >10,000 signify that there was less than 50% displacement of the radioligand at that concentration. 
 
 2.3.2. [35S]GTPγS Functional Assays. Table 2.5 summarizes the results of [35S]GTPγS 
functional assays of reference compounds for validation. For agonists, potency was reported as 
EC50 ± S.E.M. (nM), while efficacy was reported as %Emax ± S.E.M. 10 µM DAMGO was used as 
the 100% efficacy standard at the µ receptor. 1 µM DPDPE was used as the 100% efficacy 
standard at the δ receptor. 10 µM U69,593 was used as the 100% efficacy standard at the κ 
receptor. 
Table 2.5. [ 35S]GTPγS results for standard opioid compounds: EC 50 and % Emax. 
 
µ δ κ 
EC50 %Emax EC50 %Emax EC50 %Emax 
DAMGO 21 ± 2.7 100 N.D. N.D. N.D. N.D. 
DPDPE N.D. N.D. 7.3 ± 0.85 100 N.D. N.D. 
Morphine  38 ± 4.9 81 ± 2.0 N.D. N.D. N.D. N.D. 
 
[35S]GTPγS assays were performed in CHO cells transfected with and overexpressing the human opioid receptor 
subtypes. EC50 and %Emax values in this table represent the mean + S.E.M. from replicate assays performed in 





Compounds eliciting high affinity for the µ receptor (Ki < 65 nM) and high-to-moderate 
affinity for the δ receptor (Ki < 210 nM) underwent [
35S]GTPγS functional studies to determine 
agonistic and antagonistic activity at the respective opioid receptor subtypes. However, UMB 
437, 440 and 449 were not tested because the competition binding results did not offer any 
additional SAR of significance. EC50 and %Emax values were calculated to determine the 
agonistic potency and efficacy, respectively. Table 2.6 depicts the respective EC50 and %Emax 
values for UMB compounds at the respective opioid receptor subtypes. Specifically, UMB 378, 
425 and 426 are the three compounds that exhibit the highest efficacy of the compounds tested. 
UMB 425 displays µ agonistic properties similar to that morphine (EC50 = 38 ± 4.9 nM, %Emax = 
81 ± 2). pA2 values were calculated to determine the antagonistic potency at the δ receptor. 
Table 2.7 shows that both UMB 425 and 426 display competitive antagonistic effects at the δ 
receptor.  
Table 2.6. [ 35S]GTPγS results for UMB opioid ligands: EC 50 and % Emax. 
Compound 
Name 
µ δ κ 
EC50 %Emax EC50 %Emax EC50 %Emax 
UMB 246 72 ± 11 39 ± 1.3 N.D. N.D. N.D. N.D. 
UMB 375 89 49 N.D. N.D. N.D. N.D. 
UMB 376 N.D. Est. 78 N.D. N.D. N.D. N.D. 
UMB 378 250 ± 24 86 ± 1.2 N.D. N.D. N.D. N.D. 
UMB 405 32 ± 3.4 31 ± 5.0 N.D. Est. 15 N.D. N.D. 
UMB 425 35 ± 3.7 73 ± 7.3 N.D. Est. 16 N.D. Est. -2 
UMB 426 342 ± 94 79 ± 7.3 N.D. Est. 1 N.D. N.D. 
 
[35S]GTPγS assays were performed in CHO cells transfected with and overexpressing the human opioid receptor 
subtypes. EC50 and %Emax values in this table represent the mean + S.E.M. from replicate assays performed in 
triplicate. For UMB 375, the respective EC50 and %Emax values were determined from one set of replicate assays. 
UMB 376 was predicted to possess high efficacy, but was not further characterized due to solubility issues and a lack 
of compound. Additional estimated (Est.) values were based on window studies or displayed low [35S]GTPγS 
stimulation such that a sigmoidal curve could not be established. Those designated as not determined (N.D.) were 





Table 2.7. [ 35S]GTPγS results for standard opioid compounds and UMB lig ands: pA 2 
Compound Name  δ pA2 (slope)  
Naltrexone 8.19 (-0.94) 
UMB 425 6.12 (-0.91) 
UMB 426 6.31 (-1.08) 
 
[35S]GTPγS antagonism is determined by using concentrations of 1x, 3x and 10x that of the compound’s respective Ki 
for said receptor. Antagonist concentrations were used against a dose range of a standard agonist. 
 
2.3.3. µ Agonism/δ Agonism Dual-Profile CSP Model. The CSP models for the µ and δ 
receptor ligands were applied to UMB 425 as a result of its in vitro pharmacological profile. 
Predicted efficacy (%Emax) values for UMB 425 were 101 and 1.4 for the µ and δ receptors, 
respectively, values comparable to those obtained using receptor specific CHO cell lines. 
To better understand the contribution of the 5’-hydroxymethyl to efficacy, additional 
analysis was performed on conformations of UMB 425 generated during CSP model 
development. Distances and angle distributions between the basic nitrogen and oxygen in the 
5’-hydroxymethyl in UMB 425 or the 19-hydroxyl substituent in the orvinols were calculated and 
compared. Figure 2.3 shows N-O distance and N-C9-O angle probability distributions of three 
orvinols and UMB 425. In Figure 2.3, two large distributions are present that are separated by 
around 1.5 Å, although a small peak is noted in the UMB 425 distribution at 6.5 Å that overlaps 
with that of the orvinols. The N-C9-O angle indicates the relative position of the hydroxyl group 
with respect to the plane of the aromatic A-ring. The hydroxyl group of UMB 425 is slightly 
above the A-ring plane while that of the orvinols is below; however, a small overlap between 
UMB 425 and the orvinols is observed (Figure 2.3). While preliminary, these results indicate that 
UMB 425 can assume conformations in which its hydroxyl moiety participates in interactions 




Figure 2.3.  N-O distance and N-C9-O angle probability distribut ions.  (a) Images of UMB 425 and etorphine with 
the hydroxyl oxygen highlighted in red. Probability distributions of the (b) distance from basic nitrogen to hydroxyl 
oxygen and (c) the basic N-C9-oxygen angle from the simulations used in CSP model development for etorphine (red 
line), buprenorphine (green dashed line), diprenorphine (blue dashed line) and UMB 425 (purple dashed line). 
 
2.4. Discussion 
 Studies suggest that the development of a bifunctional opioid ligand depicting dual 
effects of µ agonism and δ antagonism can elicit potent analgesic properties with reduced 
tolerance liabilities compared to traditional opioid analgesics. Herein, a number of ligands were 
designed using classical opioid receptor SAR and tested for their binding affinity and 
functionality at the three opioid receptor subtypes: µ, δ and κ. CSP modeling studies were 
utilized for our most promising ligand to date, UMB 425, which displays µ agonistic effects 
comparable to morphine and, unlike morphine, displays antagonistic effects at the δ receptor 
(186). 
For the CSP modeling studies, the high efficacy at µ receptors is consistent with the 
structural similarity of UMB 425 with morphine or oxymorphone, while the low efficacy at δ 
receptors is consistent with the C-ring substituents of naltrexone. The recent availability of X-ray 
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crystal structures of the µ and δ receptors will allow for future evaluation of the present model in 
the context of 3D interactions between UMB 425, as well as other ligands, and the respective 
receptor subtypes (187, 188). 
With regards to our other ligands, UMB 449 was synthesized with the intent of increasing 
the probability of the distance from the basic nitrogen to the hydroxyl oxygen and the basic N-
C9-O angle in order to mirror the orvinol standards (Figure 2.3). This should further reinforce our 
hypothesis that the 5’ hydroxyl moiety aids in structural configurations similar to those that are 
occurring with the orvinols. 
UMB 246, 440 and 441 are a part of the benzylideneoxymorphone (“BOM”) series of 
ligands. UMB 246 shows the highest affinity at the µ receptor of the three, with equipotency for 
the δ receptor. While demonstrating promising values of potency in [35S]GTPγS assays, values 
of efficacy are markedly lower than morphine. With respect to the structural design of UMB 440 
and 441, N-phenyl substituents have previously been shown to possess higher potency than 
morphine (189). 
UMB 375-378 are a series of 3-hydroxy-4-methoxymorphinans that aim to improve δ 
selectivity with the addition of the δ-selective indole and benzylidene moieties fused to the C-
ring. Previously, 3-hydroxy-4-methoxyindolomorphinans have been shown to possess high 
affinity for the δ delta receptor with selectivity comparable to δ-selective standards naltrindole 
and oxymorphindole (190). The opening of the 4,5-bridge is hypothesized to positively influence 
δ receptor binding and selectivity (191). Affinity and selectivity ratios for UMB 377 are 
comparable to values obtained previously, some of which were obtained using modified 
radioligand binding methods from our own (190). The inclusion of the 5,14-bridge is to identify 
relative changes in binding affinity and selectivity as previously described. Based on preliminary 
results, both UMB 376 and 378 demonstrate the highest values of efficacy within this series. 
Unfortunately, the lack of high affinity and potency at the µ receptor directed our attention to 
other ligands herein. 
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UMB 406 is similar in structure to the κ-selective antagonist nor-BNI, and can be 
identified as a bivalent ligand as opposed to a bifunctional ligand. Nor-BNI is comprised of two 
naltrexone units fused at their respective C-rings by a pyrrole spacer and has been shown to 
antagonize the effects of δ-selective agonists (192). UMB 406 is comprised of two naloxone 
units fused at their respective C-rings by a pyrrole spacer. UMB 406 demonstrates selectivity for 
the κ and δ receptor subtypes to that of µ. Since UMB 406 does not fit our specific research 
interests, it appears to be best utilized as a research tool for future use. 
 Overall, additional opioid SAR profiles are difficult to decipher at this point, seeing that 
many of the ligands included are intermediate reactants, whose products will be synthesized in 
the future. The binding and functional assay data associated with these future compounds will 
provide additional opioid SAR with regards to mixed µ/δ activity. Ligands that present both 
potent agonistic properties at the µ receptor (EC50 < 50 nM, %Emax > 70%) and antagonistic 
properties at the δ receptor (pA2 > 6), specifically UMB 425, will be included in in vivo studies 
discussed in detail in Chapter 3.   
2.5. Contributions 
Jason Healy performed all competition binding and functional assays. The compounds 
were synthesized by Vani Bezawada in Andy Coop’s lab at the University of Maryland.  Jihyun 
Shim in Alex MacKerell’s lab conducted the modeling studies.  Dr. Larry Toll at Torrey Pines 










ANTINOCICEPTIVE ACTIVITY OF NOVEL UMB 




For those synthesized ligands that display the desired pharmacological profile in vitro, 
tail-flick and hot plate thermal nociceptive paradigms were designed to demonstrate the acute 
antinociceptive properties of novel UMB ligands in vivo. The tail-flick assay is traditionally used 
as a measure of spinal nociceptive responses via the ascending pain pathway discussed above, 
but has also been shown to be influenced by supraspinal signaling mechanisms (193, 194). The 
hot plate assay is a measure of supraspinal nociceptive reflexes via the descending pain 
pathway (195). The tail-flick and hot plate are common assays used for initial antinociceptive 
assessment of novel opioid ligands. Both require minimal preparation time whose nociceptive 
responses are easily distinguished. Furthermore, both the tail-flick and hot plate assays are 
Institutional Animal Care and Use Committee (IACUC) friendly as both are escapable, such that 
nociceptive stimuli is removed once response criteria or a cutoff latency has been met.  
Ligands that display high potency and efficacy at the µ receptor (EC50 < 50 nM, %Emax > 
70%) in addition to antagonism at the δ receptor (pA2 > 6) were considered for in vivo testing 
herein. UMB 425 was the first of our opioid ligands to demonstrate the mandated criteria herein. 
UMB 425 demonstrates comparable µ agonistic effects to that of morphine. Yet, surprisingly, 
UMB 425 was able to demonstrate δ-specific antagonistic properties without the inclusion δ-
specific structural moieties. Traditional opioid analgesics, including morphine, demonstrate 
agonistic effects at the δ receptor subtype.   
Morphine was chosen as the positive control for both paradigms due to its clinical 
relevance as well as for assay validation purposes with the use of previously reported results. 
Data obtained for morphine using both in vitro and in vivo assays can be used for comparisons 
when determining the potential clinical viability of novel opioid ligands herein. Both morphine 
and UMB 425 were administered subcutaneously (s.c.), intending to mimic less invasive routes, 
as opposed to intrathecal (i.t.) or intracerebroventicular (i.c.v.) routes commonly used in early 
drug development in order to conserve product. Naloxone is used for antagonist pretreatment 
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studies performed in vivo due to its clinical relevance as a drug treatment to counteract opioid 
overdose in the clinic. Furthermore, norbinaltorphimine (nor-BNI) is a κ-selective antagonist that 
can be given as a pretreatment prior to novel ligand administration to assess potential κ 
receptor induced antinociceptive properties. Due to undesirable effects associated with κ 
receptor activation (i.e. dysphoria), one of the goals of this project was to identify novel opioid 
agents with limited κ receptor interactions. While in vitro studies for UMB 425 indicate little if any 
κ-mediated agonistic properties, nor-BNI pretreatment in vivo will be performed for further 
confirmation.  
3.2. Methods 
 3.2.1. Animals. Male, Swiss-Webster mice (21-30 g, Harlan, Indianapolis, IN; Frederick, 
MD) were housed in groups of five in polysulfone cages (Techniplast, Philadelphia, PA) with a 
12:12-h light/dark cycle with food and water ad libitum. Animals were acclimated one week prior 
to experimental use and randomly assigned to treatment groups. All procedures were performed 
in accordance to the Institutional Animal Care and Use Committee at the West Virginia 
University Health Sciences Center. 
3.2.2. Hot-Plate Antinociceptive Testing. Mice were placed within a plastic cylinder (10.8 
cm ID) atop a black anodized, aluminum plate (27.9 cm x 26.7 cm x 1.9 cm) uniformly regulated 
at 53 0C (IITC Life Science Inc., Woodland Hills, CA). The latency to the first sign of excessive 
shaking, lifting and/or licking of the hind paws was determined and recorded as the behavioral 
endpoint. Two baseline latencies (BL) were recorded prior to drug administration, with an 
average BL within 8-10 sec needed for further testing. Mice were then administered either 
morphine (0.1-20 mg/kg, s.c.) or UMB 425 (0.1-20 mg/kg, s.c.) and testing latencies (TL) for 
nociceptive responses were recorded at various time points thereafter. Previous studies have 
reported that the higher doses of morphine herein will induce at or near full antinociceptive 
activity for thermal nociceptive assays (196). A similar dosing paradigm was used for UMB 425, 
since in vitro opioid binding and functional data for UMB 425 were comparable to morphine. The 
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subcutaneous route of injection was chosen because of its common usage with antinociception 
regimens. A 30 sec cutoff latency (CL) was predetermined so as to not cause tissue damage. 
Data obtained were reported as % Maximum Possible Effect (%MPE), which is indicative of 
antinociceptive activity associated with a particular compound. %MPE is determined using the 
following formula: %MPE= [(TL-BL)/(CL-BL)] x 100. 
3.2.3. Tail-Flick Antinociceptive Testing. Mice were placed in restraints (2.5 cm ID x 10.2 
cm length) and their tails were placed underneath an overhead halogen light source (IITC Life 
Science Inc., Woodland Hills, CA) whereby the latency to the first sign of a rapid tail flick was 
determined and recorded as the behavioral endpoint. Two BL values were recorded prior to 
drug administration, with an average BL within 2-4 sec needed for further testing. Animals were 
then administered test compound at dosages reported for hot plate antinociceptive testing and 
TL values recorded at various time points thereafter. A 10 sec CL was predetermined so as to 
not cause tissue damage. %MPE values were determined as described above. 
3.2.4. Antagonist Studies. Naloxone and nor-BNI were purchased from Sigma Aldrich 
(St. Louis, MO). To determine the opioid receptors involved in the antinociceptive effects of 
UMB 425, mice were pretreated with the non-selective opioid antagonist naloxone (1 mg/kg i.p., 
t = -30 min) or the κ-selective antagonist nor-BNI (30 mg/kg i.p., t = -24 h). Antinociceptive 
testing was performed 30 min after subcutaneous administration of an ED90 dose of morphine or 
UMB 425. The selected antagonist dosages and pretreatment time points have been shown to 
correspond with the intended opioid receptor subtype and peak antagonist effect (197, 198). 
3.2.5. Data Analysis. For in vivo antinociceptive assays, agonist ED50 values were 
calculated using a non-linear regression model. For antagonist studies, a one-way analysis of 
variance (ANOVA) followed by Tukey’s post-hoc tests were used to determine significance 
between groups. For all analyses, p < 0.05 was considered statistically significant. GraphPad 





 3.3.1. Thermal Antinociceptive Testing. Mice given subcutaneous injections of morphine 
and UMB 425 both demonstrated antinociceptive effects in a time- and dose-dependent manner 
for the thermal nociceptive assays (Figure 3.1). Table 3.1 summarizes respective ED50 values 
for morphine and UMB 425 from testing performed 30 min after drug treatment. The potency of 
the antinociceptive activity of UMB 425 (ED50 = 4.30 and 8.83 mg/kg for the hot plate and tail-
flick assays, respectively) was comparable to morphine (ED50 = 2.73 and 6.85 mg/kg for the hot 
plate and tail-flick assays, respectively). While not as potent as other opioid compounds 
previously tested (199), UMB 425 was able to achieve a maximal antinociceptive respsonse at 
comparable doses to morphine. 
 
Figure 3.1. Acute dose- and time-response curves fo r s.c. morphine and UMB 425 treatment for the hot p late 
and tail-flick assays.  Male, Swiss-Webster mice were treated with morphine (0.1-20 mg/kg, s.c.) or UMB 425 (0.1-
20 mg/kg, s.c.). Latencies were recorded 30 min after drug administration and every 20 min thereafter for 150 or 210 
min. (a) Dose- and time-response curves for s.c. morphine in the hot plate assay. (b) Dose- and time-response 
curves for s.c. morphine in the tail-flick assay. (c) Dose- and time-response curves for s.c. UMB 425 in the hot plate 
assay. (d) Dose- and time-response curves for s.c. UMB 425 in the tail-flick assay. 
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ED50 (mg/kg)  Morphine  UMB 425 
Hot Plate 2.73 4.30 
Tail-Flick 6.85 8.83 
 
Table 3.1. ED50 values for morphine and UMB 425 in the acute treat ment paradigm.  Summary of antinociceptive 
activity of acute morphine (0.1-20 mg/kg, s.c.) and UMB 425 (0.1-20 mg/kg, s.c.) treatment in Swiss, Webster mice 
for the hot plate and tail-flick assays. Respective ED50 values (in mg/kg, s.c.) were obtained at the 30 min time point 
after drug administration.  
 
3.3.2. Antagonist Studies. To corroborate opioid-induced antinociception, various 
antagonist pretreatments were given in conjunction with UMB 425 administration. One-way 
analysis of variance (ANOVA) indicated differences amongst mice pretreated with saline, 
naloxone and nor-BNI (F(2,12) = 8.88, p < 0.005; F(2,13) = 22.61, p < 0.0001 for the hot plate 
and tail-flick assays, respectively). UMB 425’s partial agonistic effects through the µ receptor 
appear primarily responsible for the observed antinociceptive effects seen in vivo as naloxone 
significantly attenuated UMB 425-mediated antinociception (Figure 3.2; q = 4.55, p < 0.05; q = 
8.48, p < 0.001 for the hot plate and tail-flick assays, respectively; Tukey’s post-hoc). In 
contrast, pretreatment with the κ antagonist nor-BNI failed to significantly attenuate UMB 425-
mediated antinociception (Figure 3.2; q = 0.01, n.s.; q = 1.39, n.s. for the hot plate and tail-flick 
assays, respectively; Tukey’s post-hoc). Consistent with the lack of agonist activity observed in 
the [35S]GTPγS assay at κ receptors by UMB 425, the κ receptor does not appear to contribute 





Figure 3.2. Antagonism of UMB 425 antinociception u sing various opioid antagonists.  Male, Swiss Webster 
mice received a pre-treatment of the non-selective opioid antagonist, naloxone (1 mg/kg, i.p. t = -30 min) or the κ-
selective antagonist, nor-BNI (30 mg/kg, i.p. t = -24 h) prior to an s.c. injection with an ED90 dose of UMB 425 (15 
mg/kg). Latencies were determined 30 min after UMB 425 administration. (a) Antagonism of UMB 425 antinociception 
in the hot plate assay by naloxone, but not nor-BNI. * p < 0.05. (b) Antagonism of UMB 425 antinociception in the tail-
flick assay by naloxone, but not nor-BNI. *** p < 0.001. 
 
3.4. Discussion 
UMB 425 is the first proposed ligand to be tested in vivo due to comparable µ agonistic 
effects to that of morphine seen in vitro. A similar dosing paradigm is used for UMB 425, since 
in vitro µ receptor binding and functionality for UMB 425 were comparable to morphine. These 
data show that UMB 425’s mixed µ agonist/δ antagonist effects seen in vitro, translate well to 
antinociceptive effects seen in vivo.  
Results seen in Figure 3.1 suggest that the acute antinociceptive effects for UMB 425 
are sustained longer than morphine. Differing pharmacokinetic and pharmacodynamic profiles 
between UMB 425 and morphine can explain this disparity.  
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With regards to sustained antinociceptive effects seen in the tail-flick to that of the hot 
plate assays, as discussed previously, both assays are associated with differing pathways in 
response to thermal nociceptive stimuli. Respective ED50 values obtained for both morphine and 
UMB 425 at the 30 min time point were comparable (Table 3.1), indicating similar 
antinociceptive effects between the two assays. These results demonstrate that UMB 425 is 
able to induce its antinociceptive effects through both ascending and descending pain signaling 
pathways. 
Stress induced analgesia is a potential problem that exists for the thermal nociceptive 
assays that can potentially create problematic bias within these data (200). During acute 
studies, mice are enclosed in a plastic restraint with an exposed tail for over three hours, 
potentially stressful for mice not previously exposed to the plastic restraint. To limit experimental 
bias, mice were acclimated to the plastic restraints 30-60 min the day prior and the day of 
testing. In addition, drug solutions are prepared by outside individuals not responsible for data 
collection in order to limit observer bias.  
Pretreatment studies using naloxone are performed to confirm opioid-induced 
antinociceptive effects. As expected, naloxone is able to abolish the antinociceptive effects upon 
UMB 425 administration. As shown in the previous chapter, UMB 425 has comparable binding 
affinity for the κ receptor to that of the δ receptor, suggesting potential κ-mediated effects. 
However, nor-BNI pretreatment is unable to attenuate the antinociceptive effects of UMB 425 as 
expected, ensuring that UMB 425 induces little, if any, of its antinociceptive properties through 
the κ receptor. In the future, pretreatment with the µ-selective antagonist β-funaltrexamine (β-
FNA) will further corroborate that UMB 425 induced antinociception is mediated through the µ 







Jason Healy performed the thermal antinociceptive experiments as well as the antagonist pre-
treatment studies. UMB 425 was synthesized by Padmavani Bezawada in the laboratory of Dr. 












EVALUATION OF TOLERANCE LIABILITIES OF 




Opioid induced tolerance is one of several alarming adverse effects produced by chronic 
use, especially since nearly 90% of all chronic pain patients are administered opioids (178, 
202). Tolerance necessitates that increased dosing be provided to individuals in need of pain 
relief. However, increased dosing also runs the risk of a patient experiencing additional opioid 
mediated adverse effects, including physical and psychological dependence (21). As such, the 
end goal of this project is to identify a novel opioid ligand with potent antinociceptive effects with 
reduced tolerance liabilities. Therefore, lower therapeutic doses would be needed for pain relief 
and adverse side effect risks minimized.  
As discussed above, several multicomponent opioid-based pharmacotherapies have 
shown reduced tolerance of antinociceptive effects, specifically by antagonizing the δ receptor 
subtype. In addition, several other non-opioid drugs offer promise with regards to reduced 
tolerance liabilities in conjunction with traditional µ agonists. Excessive activation of N-methyl-D-
aspartate (NMDA) receptors due to nociceptor-induced glutamate release can cause central 
sensitization; central sensitization can result in excessive responses from nociceptive stimuli 
and also reduce opioid analgesic sensitivity (94). As such, concurrent administration of an 
NMDA antagonist with a traditional µ agonist may attenuate tolerance liabilities. In fact, 
methadone possesses NMDA antagonistic capabilities and is able to attenuate morphine 
induced tolerance development (203). However, methadone still possesses potential tolerance 
and dependence liabilities (204, 205). In addition, certain NMDA antagonists have unfavorable 
side effect profiles, including acute neurodegenerative changes and psychotic reactions, 
thereby limiting their potential use in the clinic (206, 207). In addition, peptidase inhibitors that 
prolong the effects of opioid neuropeptides also provide possibilities in reducing tolerance 
development when administered simultaneously with traditional µ agonists (208). However, as 
previously discussed, a multicomponent pharmacotherapy can lend concerns regarding drug 
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misuse and diversion. As such, a single component pharmacotherapeutic agent is most 
advantageous for the treatment individuals suffering from moderate-to-severe pain. 
Our tolerance regimen was performed using previously published methods, with some 
modifications (156, 196). In order to identify discernible differences in tolerance development, 
animals were given ED90 doses of morphine or UMB 425 twice daily and underwent thermal 
nociceptive testing until a significantly higher level of antinociception was observed for UMB 425 
to morphine in both the tail-flick and hot plate assays. This paradigm ensures distinguishable 
right-ward shifts seen in subsequent dose-response challenges. 
4.2. Methods 
 4.2.1. Animals. Male, Swiss-Webster mice (21-30 g, Harlan, Indianapolis, IN; Frederick, 
MD) were housed in groups of five in polysulfone cages (Techniplast, Philadelphia, PA) with a 
12:12-h light/dark cycle with food and water ad libitum. Animals were acclimated one week prior 
to experimental use and randomly assigned to treatment groups. All procedures were performed 
in accordance to the Institutional Animal Care and Use Committee at the West Virginia 
University Health Sciences Center. 
 4.2.2. Tolerance to Thermal Antinociceptive Effects. Mice were administered twice daily 
(8 AM and 8 PM) subcutaneous injections of a test compound at respective ED90 doses for a 
five day period. On Day 6, animals were given varying doses of morphine (0.1-20 mg/kg) or 
UMB 425 (0.1-20 mg/kg) and antinociceptive activity was determined using both the hot plate 
and tail-flick assays to determine tolerance development. Respective ED50 values determined 
during the tolerance assay were then compared to values obtained in the acute treatment 
paradigm. On Days 1-5, the order of the antinociceptive measurements were counterbalanced 
so that half the mice were assessed for hot plate latencies in the AM and tail-flick latencies in 
the PM; the other half were tested for tail-flick latencies in the AM and hot plate latencies in the 
PM. On Day 6, animal test latencies were determined, first with the tail-flick assay followed 15 
min later by the hot-plate assay.  
63 
 
 4.2.3. Data Analysis. For the tolerance assay, repeated measures one-way ANOVA 
followed by Dunnett’s post-hoc tests were used to determine significance between treatment 
days for test compound treatment. Repeated measures two-way ANOVA and Bonferroni’s post-
hoc tests were used to determine significance between groups. For all analyses, p < 0.05 was 
considered statistically significant. GraphPad Prism (San Diego, CA) was used for all data 
analyses. 
4.3. Results 
4.3.1. Tolerance to Thermal Antinociceptive Effects. The results of administration of ED90 
doses of morphine and UMB 425 to mice twice daily for a period of five days, with test latencies 
determined 30 min after drug administration are summarized in Figure 4. One-way repeated 
measures ANOVA demonstrated statistical differences amongst treatment days for morphine 
administration in both the hot plate (Figure 4.1a; F(4,76) = 15.22, p < 0.0001) and tail-flick 
assays (Figure 4.1b; F(4,76) = 8.52, p < 0.0001). Dunnett’s post-hoc analysis revealed that 
morphine administration significantly decreased antinociceptive activity on Day 4 and 5 of the 
tolerance paradigm for both the hot plate (Figure 4.1a; q = 4.45, p < 0.01; q = 6.52, p < 0.01; 
respectively) and tail-flick assays (Figure 4.1b; q = 2.72, p < 0.05; q = 5.12, p < 0.01; 
respectively). One-way repeated measures ANOVA also demonstrated statistical difference 
amongst treatment days for UMB 425 administration in the hot plate assay (Figure 4.1a; F(4,84) 
= 9.32, p < 0.0001) but not for the tail-flick assay (Figure 4.1b, F(4,76) = 1.53, n.s.). Dunnett’s 
post-hoc analysis revealed that UMB 425 administration significantly decreased antinociceptive 
activity on Day 4 and 5 of the tolerance paradigm in the hot plate assay (Figure 4.1a; q = 3.43, p 
< 0.01; q = 5.11, p < 0.01; respectively). 
Two-way repeated measures ANOVA revealed statistical differences between morphine 
and UMB 425 treatment in time points for both the hot plate (Figure 4.1a; p < 0.0001) and tail 
flick assays (Figure 4.1b; p < 0.0001). Bonferroni’s post-hoc analysis demonstrated that UMB 
425 maintained statistically greater antinociceptive activity than morphine on Day 4 and 5 for the 
64 
 
hot plate assay (Figure 4.1a; t = 2.86, p < 0.05; t = 4.15, p < 0.001; respectively)  and on Day 5 
for the tail-flick assay (Figure 4.1b;  t = 2.88, p < 0.05).  
Our tolerance paradigm involves thermal nociceptive testing on a daily basis to ensure 
that a statistical difference in antinociceptive activity is seen between morphine and UMB 425 
prior to a dose-response challenge. Table 4.1 summarizes respective ED50 values for morphine 
and UMB 425 from the dose-response challenge on Day 6 of the tolerance paradigm. UMB 425 
(ED50 = 12.96 and 11.58 mg/kg for the hot plate and tail-flick assays, respectively) produced 
markedly less tolerance development than morphine (ED50 = 21.31 and 44.11 mg/kg for the hot 
plate and tail-flick assays, respectively), as evident by the respective rightward shifts in ED50 
values (7.8- vs. 3.0-fold and 6.4- vs. 1.3-fold for morphine vs. UMB 425 in the hot plate and tail-
flick assays, respectively).  
 
 
Figure 4.1.  Antinociceptive tolerance development for morphine and UMB 425 for the hot plate and tail-flick 
assays.  Male, Swiss-Webster mice were given an ED90 dose of morphine (15 mg/kg, s.c.) or UMB 425 (15 mg/kg, 
s.c.) twice daily for a five day period. Latencies were determined 30 min after drug administration. (a) Antinociceptive 
tolerance development in the hot plate assay. ** p < 0.01 vs. Morphine Day 1/UMB 425 Day 1; # p < 0.05 vs. 
Morphine Day 4; ### p < 0.001 vs. Morphine Day 5. (b) Antinociceptive tolerance development in the tail-flick assay. 

















Morphine UMB 425 
Tolerance Shift Tolerance Shift 
Hot Plate 21.31 7.8 12.96 3.0 
Tail-Flick 44.11 6.4 11.58 1.3 
 
Table 4.1. ED50 values for morphine and UMB 425 in the tolerance tr eatment paradigms.  Summary of 
antinociceptive activity obtained for the tolerance paradigm for morphine and UMB 425 for the hot-plate and tail-flick 
assays. Mice were treated with the ED90 dose of morphine (15 mg/kg) or UMB 425 (15 mg/kg) determined in the 
acute treatment paradigm, twice a day for five days. ED50 values for the tolerance paradigm were obtained during a 
dose-response challenge on Day 6 of treatment, whereby latencies were determined 30 min after drug administration 




UMB 425 maintains greater levels of antinociceptive activity compared to morphine 
during a six day paradigm used to mimic opioid-induced chronic tolerance. Dose-response 
curves generated on Day 6 using varying doses of UMB 425 or morphine indicate a greater 
right-ward shift in respective ED50 values for morphine compared to UMB 425. While we used 
male, Swiss-Webster mice, respective ED50 shifts in the morphine-treated tolerance paradigm 
seen on Day 6 were comparable to tolerance paradigms previously performed using male ICR 
mice (156). Regimen variations regarding drug dosing, route of administration, number of 
injections per day as well as the time length of the paradigm can lead to slight variations. 
The antagonistic potency of UMB 425 through the δ receptor reported in Chapter 2 (pA2 
= 6.12) is lower than previously highlighted µ agonist/δ antagonist analgesics, notably 11-(4-
chlorophenyl)-7-(cyclopropylmethyl)-8a-(3-phenylpropoxy)-6,7,8,8a,9,13b-hexahydro-5H-4,8 
methanobenzofuro[3,2-h]pyrido[3,4-g]quinolin-1-ol or  “17d” (δ Ke = 0.091 ± 0.01 nM) (155), as 
well as the δ-selective antagonist naltrindole (pA2 = 10.92) (186). Yet, UMB 425 demonstrates a 
significant reduction in tolerance liabilities compared to morphine itself, specifically a 2.6- and 
4.9-fold reduction in respective ED50 shifts for the hot plate and tail-flick assays. The recently 
reported mixed µ agonist/δ antagonist analgesic 17d was found to have a 5.6-fold decrease in 
respective A50 shifts compared to morphine itself in the warm-water tail-withdrawal assay (155). 
The respective shift-fold variations between the in vivo studies are thus quite comparable 
despite the lower affinity and antagonist potency of UMB 425 compared to 17d for the δ 
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receptor in vitro. Thus, equipotence at the µ and δ receptor does not seem required to improve 
tolerance liabilities of opioid analgesics. 
The molecular mechanisms surrounding opioid-induced tolerance are still not clear, 
although many efforts have been taken to discern the labyrinth of potential components 
involved. Morphine, a partial µ agonist, is unable to properly internalize the µ receptor upon 
activation, whereby desensitization and uncoupling of the G-protein lead to the development of 
tolerance (103). δ receptor recruitment to the plasma membrane has been shown to increase 
with extended exposure to µ agonists (209). Furthermore, δ antagonists can provide synergistic 
effects in combination with µ agonists that enhances µ receptor binding and signaling in cells 
expressing µ-δ hetero-dimers, potentially through altered G-protein activation (131). It is 
conceivable that the µ agonist/δ antagonist interactions through UMB 425 allow for proper 
internalization, driven by the δ receptor in the hetero-oligomeric complex, and subsequent µ 
receptor mediated recycling and resensitization thereby leading to reduced tolerance 
development.  
In addition, G protein recruitment may be altered upon UMB 425 administration, 
compared to chronic administration of traditional µ agonists or opioid naive systems. Opioid 
receptors induce their inhibitory effect through the Gi/o family of G-proteins. However, opioid 
receptors have also been linked to Gz proteins, which, as a part of the Gi family, induce similar 
inhibitory effects, as well as Gs proteins, which induce upregulation of cAMP and subsequent 
downstream effectors. Studies have shown that µ-δ hetero-oligomers switch G-protein 
preference from Gi to Gz (210). Interestingly, Gz proteins recruited by µ receptors are not 
involved in sensitization of AC (49), suggesting reduced tolerance liabilities associated with Gz 
protein recruitment. Furthermore, Gz deficient mice develop tolerance to morphine at a faster 
rate and to a greater degree than their wild-type counterparts (211).  
Lastly, GPCR kinase (GRKs) and β-arrestin regulatory processes have been linked to 
opioid-induced tolerance (212). Concurrent µ agonist/δ antagonist activity may alter 
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phosphorylation and recruitment mechanisms involved with these processes, potentially limiting 
GPCR desensitization. Follow up studies will be needed to delineate the underlying 
mechanisms through which UMB 425 reduces the development of tolerance compared to 
morphine. 
4.5. Contributions 
Jason Healy performed the tolerance regimens using thermal nociceptive apparatuses. UMB 
425 was synthesized by Padmavani Bezawada in the laboratory of Dr. Andrew Coop at the 























The studies herein demonstrate that a mixed µ agonist/δ antagonist opioid analgesic is 
able to reduce tolerance liabilities with chronic administration without demonstrating 
equipotency for both the µ and δ receptor subtypes. UMB 425, a 5,14-bridged morphinan-based 
orvinol precursor lacks δ-selective motifs fused to the C-ring of the traditional opioid 
pharmacophore. CSP models predicted that UMB 425 would demonstrate high efficacy at the µ 
receptor with near pure antagonist capabilities at the δ receptor. [35S]GTPγS functional assays 
confirmed these predictions in CHO cells transfected with and overexpressing the respective 
human opioid receptor subtypes. UMB 425 displayed potent antinociceptive effects in vivo, 
comparable to morphine, which was subsequently blocked by naloxone pretreatment. During a 
six day tolerance paradigm, UMB 425 was able to maintain significantly higher levels of 
antinociception compared to morphine. 
5.2. Future Studies and Direction 
 5.2.1. Future studies involving UMB 425. The results herein for UMB 425 are promising, 
though additional studies need to be performed in order to develop a more comprehensive 
pharmacological profile. From a clinical stand point, the concerns surrounding respiratory 
depression and constipation liabilities are most concerning. Traditional µ agonists used for pain 
management have been shown to decrease both respiration as well as gastrointestinal motility 
(21). Research has shown that δ-selective antagonists can attenuate respiratory depression 
liabilities (213) and promote colonic propulsion (214). Blood gas analysis and whole body 
plethysmography paradigms can be used for extensive respiration studies in vivo (215-217). 
Charcoal meal and ricinus oil paradigms are used to assess alterations in gastrointestinal 
motility and propulsion in vivo (218, 219).  
Furthermore, long-term pain management that includes chronic µ agonist administration 
can leave a patient more susceptible to the damaging side effects of psychological and physical 
dependence (21). δ-selective antagonists and δ opioid receptor knockout mice have been 
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shown to attenuate the rewarding properties of morphine (220, 221). Conditioned place 
preference and self-administration paradigms can assess the psychological rewarding effects 
associated with UMB 425 administration (222, 223). In addition, mixed µ agonist/δ antagonist 
opioid analgesics have been shown to reduce physical dependence liabilities (156). Physical 
dependence liabilities can be assessed by acute and chronic administration of UMB 425 prior to 
naloxone administration to precipitate and assess withdrawal symptoms; symptoms include 
vertical jumps, teeth chattering, wet-dog shakes, tremors and diarrhea (76, 156).  
 UMB 425 should also be tested for its antinociceptive effects using tonic nociceptive 
stimuli. The two thermal nociceptive testing apparatuses, hot plate and tail-flick, used for in vivo 
studies herein are succinct and escapable and thus indicative of phasic nociceptive stimuli 
(195). Physiological adaptations have been shown to occur as a result of chronic pain and are 
thought to manifest in paradigms of tonic nociceptive stimuli, such as the writhing (224) and 
formalin assays (225-227). Chemically induced visceral nociception is observed during writhing 
assays, while the formalin and Freund’s adjuvant assays can be used to demonstrate 
inflammatory nociception (195, 228). The orvinol buprenorphine is a unique opioid analgesic 
with mixed µ agonist/δ antagonist properties that has been shown to induce differing 
antinociceptive responses via phasic nociceptive stimuli to that of tonic nociceptive stimuli (229). 
UMB 425 may interact with the respective receptor subtypes similarly to that of buprenorphine, 
such that differing antinociceptive responses may be plausible. Peripheral neuropathic pain is a 
result of damage to primary afferent axons and nerve inflammation (230). Since it has been 
shown that pathophysiological responses to peripheral nerve injury and acute noxious stimuli 
differ from one another (231), numerous rodent models have been devised that aim to mirror the 
underlying mechanisms associated with neuropathic pain. These models include the 
constriction and ligation of spinal nerves (232) which assess behavioral responses to 
temperature-related noxious stimuli believed to mimic the clinical pain conditions hyperalgesia 
and allodynia (233, 234). Nociceptive models of bone pain have also been devised to mimic 
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hyperalgesic and allodynic conditions (235). The von Frey test uses mechanical nociceptive 
stimuli to mimic neuropathic pain (195). An assortment of nociceptive models can provide 
further evidence as to the feasibility of UMB 425 for human use.  
In addition, further studies delineating UMB 425’s pharmacodynamic and 
pharmacokinetic properties will further attest clinical viability. Preclinical ADME studies can be 
performed to investigate the absorption, distribution, metabolism and excretion of UMB 425 both 
in vitro and in vivo. The cytochrome p450 pathway is involved in the oxidative metabolism of 
many opioid narcotics. UMB 425 treatment with human liver microsomes and cDNA-expressed 
p450’s (CYP1A2, 2C8, 2C9, 2C19, 2D6 or 3A4) can determine pharmacokinetic variables and 
identify subsequent metabolites using standard analytical techniques, including high 
performance liquid chromatography (HPLC) and liquid chromatography/tandem mass 
spectrometry (LC/MS/MS) systems (236-240). Known cytochrome p450 inducers/inhibitors can 
be examined at their respective isoforms to determine alterations in oxidative metabolism of 
UMB 425 (241). One of the primary advantages of metabolic paradigms performed in vivo is the 
determination of pharmacokinetic profiles with various routes of administration (241). Varying 
concentrations of UMB 425 can be used with blood and urine samples taken at varying time 
points and analyzed using standard analytical techniques. 
As discussed above, opioid induced tolerance has been linked to multiple GPCR 
regulatory functions, including receptor phosphorylation, internalization, desensitization and 
resensitization (103). Studies that dissect GPCR regulatory functions upon treatment with UMB 
425 will provide further examination on to the underlying mechanisms associated with mixed µ 
agonist/δ antagonist opioid ligands and reduced tolerance liabilities. Whole cell phosphorylation 
assays can be performed via imunnoprecipitation studies utilizing epitope tagged cells 
expressing both the µ and δ receptor subtypes under various treatment regiments, including 
UMB 425 in addition to DAMGO and morphine controls (242). cAMP accumulation studies can 
be performed to determine the desensitization/resensitization effects in the presence of UMB 
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425 (242); studies which will further explore the AC superactivation theory of tolerance 
development with respect to UMB 425. Endocytotic studies can be performed using 
fluorescently labeled epitope tagged cells that determine receptor internalization levels upon 
exposure to UMB 425 and agonist controls (242). Furthermore, bioluminescence resonance 
energy transfer (BRET) assays can be utilized to determine UMB 425-induced G protein 
preference under varying experimental conditions (210). The GPCR regulatory protein β-arrestin 
2 has been shown to induce differing cellular responses depending on µ agonist treatment. 
Chronic morphine administration does not induce tolerance development in β-arrestin 2 
knockout animals; however, chronic administration of methadone, fentanyl, and oxycodone 
show no difference in tolerance development compared to wild type animals (243). Chronic 
UMB 425 antinociceptive effects can be assessed using β-arrestin 2 knockout animals to further 
delineate the role of β-arrestin 2 in opioid-induced tolerance.  
These studies can and should be performed using alternative forms of pain management 
pharmacotherapy to ensure that UMB 425, or any another ligand identified within this series, 
serves as the best combination of reducing pain while minimizing side effect liabilities. Pre-
clinical studies performed in vitro and in vivo can provide initial assessments; however, further 
assessment in the clinic will provide medical care providers with the most pertinent information. 
Unfortunately, the fact remains that we still have yet to identify discernible factors that can 
pinpoint chronic pain patients for opioid narcotic misuse and diversion, a fact which concerns 
physicians of potential legal ramifications. As such, federal and state agencies have 
implemented laws and programs, including prescription monitoring programs (PMPs), to not 
only circumvent prescription opioid diversion and abuse but also to ensure that patients are not 
denied prescriptions opioids when necessary (159, 173). Reports have shown that past histories 
of alcohol and drug abuse and criminal convictions are statistically higher risk factors associated 
with prescription opioid misuse (244). Yet, one of the best ways for the physician to ensure 
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patient compliance is to develop prescription management plans which include treatment goals, 
follow-up scheduling and urine testing if necessary (245).   
 5.2.2. Future studies involving additional opioid ligands targeted for mixed µ agonist/δ 
antagonist profiles. UMB 425 is a 5,14-bridged morphinan-based precursor. Opioid SAR has 
previously shown that structural modifications made to the 6,14-bridge associated with the 
orvinols and related opioids can possibly influence both binding affinity and functionalities at the 
respective opioid receptor subtypes (170, 171). Additional compounds can and will be 
synthesized that better delineate the SAR between the 5,14-bridge and the δ-selective motifs 
fused to the C-ring, including the indole group of the indolomorphinans and the benzylidene 
moiety in the opioid benzylidenes.  
Questions regarding equipotency between µ and δ and tolerance development can be 
further explored. Since UMB 425 does not possess traditional δ-selective motifs, we can step 
back and reexamine the µ agonist/δ antagonist assumptions previously made. For UMB 425, 
the 5’-hydroxymethyl substituent is hypothesized to possess the necessary δ antagonistic 
properties that aids in tolerance reduction. CSP modeling studies herein have demonstrated 
probabilistic overlaps between UMB 425 and orvinol standards with regards to conformational 
distances and angles. The most recent compound tested, UMB 449, has extended the 5’-
hydroxymethyl into a 5’-hydroxypropyl substituent chain. This slight structural modification 
should improve upon the probabilistic overlap for the distance between the basic nitrogen and 
the hydroxyl oxygen and mirror results seen for the orvinol standards. These modifications will 
provide further insight into the binding affinity and level of functionality necessary for the δ 
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